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ABSTRACT 
The increased prevalence of antibiotic resistance threatens to render all of our current 
antibiotics ineffective in the fight against microbial infections. Biofilms, or microbial communities 
attached to biotic or abiotic surfaces, have enhanced antibiotic resistance and are associated with 
chronic infections including periodontitis, endocarditis and osteomyelitis. The “biofilm lifestyle” 
confers survival advantages against both physical and chemical threats, making biofilm eradication 
a major challenge. A need exists for anti-biofilm treatments that are “anti-pathogenic”, meaning 
they act against microbial virulence in a non-biocidal way, leading to reduced drug resistance. A 
potential source of anti-biofilm, anti-pathogenic agents is plants used in traditional medicine for 
treating biofilm-associated conditions. My dissertation describes the anti-pathogenic, anti-biofilm 
activity of Rhamnus prinoides (gesho) extracts and specific chemicals derived from them.  
Rhamnus prinoides, an evergreen shrub native to east Africa, is used in the fermented 
beverages te’j and tella and to treat a variety of illnesses including atopic dermatitis. Gesho has 
antibacterial and antiplasmodial activity but little is known about its effect against microbial 
biofilms. Preliminary work determined that gesho leaf ethanol extracts inhibited Gram positive 
bacterial biofilm formation up to 99 percent without inhibiting microbial growth, suggesting an 
anti-pathogenic mechanism of activity. Fractionation, chemical analysis and activity screens 
identified ethyl 4-ethoxybenzoic acid (EEB) as a novel gesho-derived compound with anti-
pathogenic anti-biofilm activity. Structure-activity analysis of EEB-related compounds identified 
4-ethoxybenzoic acid (4EB) as a more potent anti-pathogenic compound against S. aureus 
biofilms. 4EB inhibited 70 percent S. aureus biofilm formation with minimal impact on planktonic 
cell viability. 4EB decreased the fraction of hydrophobic S. aureus cells in culture, potentially 
reducing surface colonization. Additionally, treatments of existing biofilms with a combination of 
4EB and vancomycin synergistically decreased the viability of biofilm dwelling cells up to 85 
percent when compared to vancomycin alone. Work with gesho stem extracts measured more than 
90 percent reduction of dual-species biofilms comprised of the oral pathogens Streptococcus 
mutans and Candida albicans. Reduced biofilm formation correlated with inhibition of 
extracellular polysaccharide production. Overall, gesho extracts and gesho-derived compounds 
have potential for use in topical and oral hygiene products, for wound treatments and other anti-
biofilm applications. 
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1 
1 INTRODUCTION  
1.1 Microbial biofilms 
Biofilms are recalcitrant, complex, microbial communities that form on solid surfaces and 
can result in both acute and chronic illnesses. The biofilm lifestyle confers survival advantages 
against both physical and chemical threats that would easily eliminate their free-floating, 
planktonic counterparts; thus in nature, most microbes exist in biofilm communities. Biofilms form 
on a variety of surfaces including on water filters, inside industrial pipes, inside bioreactors and 
on animal tissues. In many cases, biofilms pose no threat to humans and often have beneficial 
applications however, when associated with human pathogens, they can be the root of chronic 
illnesses and facilitate the spread of antibiotic resistance. 
1.1.1 The biofilm life cycle 
The biofilm life cycle has four main stages: attachment, proliferation, maturation and 
detachment. Attachment occurs when free-floating, planktonic microorganisms in a liquid media 
interact with and anchor onto a solid substrate. Attachment can be reversible or irreversible with 
the later initiating the biofilm formation process. Both cellular characteristics (such as charge, 
hydrophobicity and appendage prevalence) and substrate features (including hydrophobicity, 
charge, composition, porosity and texture) play a role in attracting and anchoring organisms to a 
surface (1). Once attached, organisms will begin to proliferate, forming a thin film of cells on the 
substrate. As cellular proliferation continues and the biofilm matures, the direction of spread often 
switches from lateral to aerial, resulting in the formation of column or mushroom-like structures 
that protrude into the liquid media. These structures are made possible by the presence of a dense, 
cell-derived matrix of metabolites known as the extracellular polymeric substance (EPS) (2). The 
EPS is primarily composed of polysaccharides, proteins and extracellular DNA that work together 
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to provide structure as well as protection to the biofilm. As mass increases, biofilms becomes so 
dense that oxygen and vital nutrients are no longer able to effectively reach the older cells residing 
deep within the matrix (3, 4). The lack of available resources, coupled with the accumulation of 
both intra- and intercellular signaling molecules, leads the next stage in the biofilm life cycle, 
detachment (5). During detachment, parts of the biofilm become dislodged and travel to satellite 
locations where new biofilms can be established; this process is known as dispersal (5, 6). Biofilm 
dispersal exacerbates the infection and worsens both treatment efficacy and patient prognosis. 
1.1.2 Biofilms and antibiotic resistance 
Microbial biofilms exhibit a variety of characteristics that make them difficult to eradicate 
once formed. Low metabolic rates, persister cells, horizontal gene transfer and the extracellular 
matrix are all major factors that decrease the efficacy of both chemical and physical biofilm 
removal (7). 
1.1.2.1 The matrix 
The biofilm extracellular polymeric substance (EPS) is a complex matrix composed of 
polysaccharides, proteins and nucleic acids that work together to provide structure and protection 
to the biofilm and its inhabitants. The matrix is dense and sticky making penetration by antibiotics 
or immune cells challenging (2). Extracellular nucleic acids (primarily eDNA) are released into 
the matrix via cell lysis, active secretion or release from membrane vesicles. eDNA has been found 
to play a role in biofilm structure and antibiotic resistance through binding of cationic antibiotics 
(8–11).  
Matrix proteins, another primary contributor to the biofilm structure, has been found to be 
important for the initial attachment of cells to surfaces and in cell accumulation (12, 13). Matrix 
proteins can be either secreted or anchored to the cell well (CWA) (12, 14). CWA proteins have 
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been found to engage in both homo- and heterodimerization with surrounding microbial and host 
derived proteins, anchoring the microbial cells within the biofilm to each other and to host tissues 
(12, 14, 15). Interestingly, some biofilm associated proteins have been found to stimulate the 
production of other matrix components including extracellular DNA and polysaccharides, further 
enhancing biofilm formation (16).  
Matrix polysaccharides make up a significant proportion of the biofilm matrix and perform 
similar functions as eDNA and matrix proteins. Matrix polysaccharide composition varies widely 
between microbial species and is greatly impacted by environmental conditions; despite this 
variability, most have been found to aid in cell aggregation, biofilm structural integrity and 
antibiotic resistance (17, 18). As in the case of biofilm proteins, biofilm carbohydrates have been 
found to be essential for proper assembly and maturation of biofilms with deficient mutants 
resulting in unusual biofilm morphologies or lacking the ability for form biofilms all together (19). 
Additionally, matrix polysaccharides have been found to actively bind antimicrobial peptides (20) 
and prevent immune cell phagocytosis (18). The three major biofilm macromolecules (proteins, 
polysaccharides and nucleotide) together with less significant constituents (including lipids, 
bacteriophages and quorum sensing molecules) interact to form recalcitrant biofilms that can go 
on to establish resistant and chronic infections. 
1.1.2.2 Decreased metabolism and persister cells 
Cellular metabolism plays an important role in antibiotic efficacy with stationary-phase or 
metabolically attenuated cells exhibiting enhanced resistance to treatment when compared to their 
metabolically active counterparts (21–23). At any given time, biofilms contain cells at various 
stages in their life cycle. Cells at the biofilm perimeter are generally metabolically active while the 
majority of cells that reside at the base or in the interior of the biofilm column are in stationary 
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phase due to limited availability of resources such as nutrients and oxygen (3, 24, 25). The lack of 
metabolic activity exhibited by these senior biofilm-dwelling cells helps to protect them from 
biocidal and bacteriostatic antibiotics (22, 24). One method that has been found to reverse this 
form of resistance is to supplement antibiotic treatments with vital metabolites (22, 26). The 
metabolites stimulate microbial metabolism, restoring sensitivity to previously tolerant or resistant 
cells.  
Unfortunately, resting or stationary phase cells are not the only population of biofilm-
residing cells that exhibit inherent resistance to antibiotic treatment. Biofilms contain a 
subpopulation of antibiotic-tolerant, dormant cells known as persister cells that aid in biofilm 
longevity and infection persistence. Persister cells are genotypically identical but phenotypically 
distinct variants of microbial wildtype strains (27). They result from environmental stressors that 
trigger the expression of genes such as toxin-antitoxin modules that halt metabolism, translation 
and replication (28, 29). Persister cells can be found at every stage of growth as long as stressors 
such as nutrient and oxygen deprivation are present (30, 31). Despite the ubiquitous impact of the 
stressor, only a small subset of the total biofilm population (less than 1 percent) will go on to 
become persister cells (4, 27, 30, 31). The dormant nature of persister cells makes them highly 
tolerant to antibiotic treatments, requiring excessively high treatment concentrations to begin 
eliciting a biocidal response (27, 30, 32). This contributes to biofilm survival and chronic disease 
as standard antibiotic treatment dosages fail to eradicate these dormant cells allowing them go on 
to proliferate and reestablish infection once environmental conditions are favorable (30). This can 
lead to recurring infections and chronic illness (33, 34). 
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1.1.2.3 Heterogeneity and horizontal gene transfer 
Horizontal gene transfer in biofilms can facilitate inter- and intraspecies spread of 
antibiotic resistance genes. In nature, biofilms are heterogeneous and contain cells from a variety 
of strains and species (35). The extracellular matrix surrounding biofilm cells positions disparate 
cells in close proximity to one another, facilitating swift, intercellular exchange of cellular 
components including DNA (36). Two forms of horizontal gene transfer occur in biofilms: 
transformation and conjugation (37, 38).  Transformation is indirect and occurs when an organism 
appropriates extracellular DNA from the environment that is later incorporated into its own 
genome; conjugation, on the other hand, is the direct transfer of DNA between organisms through 
a pillus. The transfer of genetic information is especially important when it involves antibiotic 
resistance. Inter- and intraspecies transfer of antibiotic resistance genes has been observed in 
biofilms but is often limited to the actively metabolizing cells that reside on the biofilm perimeter 
(37, 38). This is thought to be due to the fact that both DNA uptake and pilli formation are energy 
expensive processes that can only be conducted by cells that are undergoing metabolism (39). 
Additionally, the ubiquitous spread of resistance genes throughout biofilms has been hypothesized 
to be hindered by the restrictive and structured nature of the biofilm matrix. Genetic information 
can only be exchanged between neighboring cells in close proximity, cells that are too distant are 
unable to interact halting further exchange. This limitation results in pockets or clusters of resistant 
communities within the matrix rather ubiquitous prevalence (39).  Despite the localized occurrence 
of horizontal gene transfer in biofilms, it still plays an important role in the spread of antibiotic 
resistance and patient outcomes especially considering that multidrug resistant (MDR) microbial 
species have, in some cases, been found to produce more biofilm than their susceptible 
counterparts (40, 41).  
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1.1.3 Biofilm infections and chronic illnesses 
Biofilm infections can result in debilitating, chronic illnesses as infections are recalcitrant 
to treatment and degrade host tissues overtime (42). Biofilms are commonly introduced into the 
body via contaminated abiotic materials such as joint replacements and catchers however, they can 
also form organically on biotic tissues as in the case of cystic fibrosis. Once introduced into the 
body, biofilm cells will bind to and invade host tissues to establish new biofilms inside the host. 
These infections begin as acute but can quickly become chronic due to the resistance mechanisms 
discussed previously (see section 1.1.2). Periodontitis, endocarditis, chronic rhinosinusitis and 
osteomyelitis are all serious illnesses that are attributed to chronic biofilm infections (43–46). 
Additionally, biofilms have been found in the wounds from chronically ill patients; these biofilms 
were not present in wounds from patients with acute infections (42). Wound colonization prevents 
healing and aids in the spread of infection to previously healthy tissues (47). Chronic biofilm 
infections such as this often require surgery or amputation to combat disease progression and when 
proper treatment is delayed, patients risk developing septicemia or death. 
1.1.4 Societal impact of biofilm infections 
Biofilm infections not only have negative health outcomes but also have serious societal 
and economic ramifications.  In 2010, in the United States, it was estimated that over 14 million 
patients presented with biofilm infections each year resulting in approximately 350,000 deaths 
annually (43). The economic ramifications of treating and caring for these patients are considerable 
for both the patient and the country as a whole. Since the 1990’s, the cost of treating biofilm related 
infections have steadily increased leaving patients with inflated medical bills totaling tens to 
hundreds of thousands of dollars (46). These exorbitant health care costs are further increased 
when infections exhibit active antibiotic resistance (antibiotic resistance genes are being 
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expressed) as additional hospitalization and care are required (46, 48–50). The average American 
citizen does not have sufficient income or financial reserves to immediately pay off such massive 
debts, leaving many struggling to pay their medical bills. In some cases, people are forced to 
sacrifice basic necessities such as food, housing and transportation in order to make healthcare 
payments (51). To make matters worse, severe infections often require the afflicted individual to 
stay home or check into a hospital in order to get well, this means increased absenteeism which 
may result in decreased income or termination of employment (46). The economic burden 
associated with biofilm infections does not solely fall on the patient but also impacts the nation as 
a whole as a significant population of the country are enrolled in Medicare or Medicaid. The United 
States has been estimated to spend over 94 billion USD on the treatment of biofilm infections each 
year with an additional estimate of 2-20 billion USD spent on the treatment of antibiotic resistant 
infections (43, 52, 53). 
The costs of antibiotic resistance and biofilm infections are not strictly monetary, impacts 
on quality of life and mental health are also prevalent. When studying a cohort of individuals who 
developed post-surgery antibiotic resistant infections, Perencevich et al., 2003 reported a 
significant decrease in overall mental and physical health in patients after surgery when compared 
to before surgery (50). A decrease in mental health was not observed in control patients and the 
reported impacts on physical health were less severe. This observation may have been due to a 
combination of financial woes, physical impairments and extensive care requirements (both in and 
outside the hospital) that come with the treatment of antibiotic resistant infections. Infections can 
also directly decrease a patient’s quality of through inhibition of mobility or ability to perform 
basic day-to-day tasks. One example can be seen in patients with severe periodontitis, an oral 
biofilm infection that may result in irreversible tooth and bone loss. For the afflicted, the lack of 
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teeth and presence of oral pain make it difficult for many to eat, speak or properly conduct oral 
hygiene practices (ie. brushing and flossing) which negatively impacts their overall physical and 
psychological health (54–56). The debilitating epidemiological, financial and social implications 
of biofilms have inspired many researchers to investigate natural products as sources of anti-
biofilm therapeutics. 
1.2 Natural products in traditional medicine and anti-pathogenic phytotherapeutics 
Humans have relied on homeopathic remedies to self-medicate for thousands of years. Prior 
to the development of modern medicine, people primarily used plant and animal products to 
alleviate symptoms and cure diseases. These treatments were commonly in the form of tonics, 
tinctures and creams whose recipes were passed down from generation to generation. Some of 
these treatments have since proven to be detrimental to human health while others are still widely 
used today (57, 58). Research into ethnopharmacologically relevant plant extracts and plant 
derived compounds have identified both anti-bacterial and anti-biofilm activities (59, 60). The 
anti-biofilm activity of many phytotheraputics have been attributed to either biocidal or biostatic 
mechanisms; in time, this can prove problematic as selective pressure may lead to the development 
of resistance. In an effort to identify novel and effective anti-biofilm agents that do not potentiate 
antibiotic resistance, investigations into anti-pathogenic phytotherapeutics have increased (61–63).  
Anti-pathogenic therapeutics are compounds that inhibit microbial virulence or pathogenesis 
while minimizing selective pressure thus delaying antibiotic resistance development (64, 65). 
Many plant extracts, essential oils and phytochemicals have been found to exhibit anti-pathogenic 
anti-biofilm activity including: Rosa rugose (beach rose), Tripterygium wilfordii (thunder god 
vine), Piper nigrum (black pepper) and Commiphora myrrha (myrrh) (59, 61, 66). Targets of anti-
pathogenic therapeutics include biofilm formation (61, 66, 67), quorum sensing signaling (59, 68), 
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hemolysis activity (61, 63) and motility (59, 66, 67). Despite the existence of many promising anti-
pathogenic therapeutics, none are currently readily available to consumers. 
1.2.1 Anti-pathogenic activity of benzoic compounds  
Benzoic compounds are ubiquitous in plant tissues and are a major category of interest in 
anti-pathogenic antimicrobial research. Benzoic acid and its derivatives consist of a core benzene 
ring and a carboxylate substituent; many plant derived benzoic compounds such as 
epigallocatechin gallate, hamamelitannin, salicylic acid and ginkgolic acid possess additional 
substituents that aid in their antimicrobial activity. Benzoic compounds have been found to exhibit 
anti-pathogenic antimicrobial activity against a variety of microorganisms including 
Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus mutans and Escherichia coli 
through targeting extracellular polysaccharide production, exoprotease activity, fimbriae 
production, quorum sensing and motility (69, 70). The use of these compounds as antibiotic 
adjuvants has gained traction in an effort to restore sensitivity to resistant strains of 
microorganisms (71–73).        
1.3 Rhanmus prinoides (gesho): more than just beer 
Rhamnus prinoides, gesho, is a buckthorn plant that grows throughout East Africa. This plant 
has been used in the production of some of the oldest fermented beverages known to man but has 
also been used traditionally for the treatment of a variety of illnesses. Research into the therapeutic 
applications of gesho extracts have identified both antimicrobial and anti-plasmodial activities. 
Antimicrobial compounds such as quercetin, emodin and chrysophanol have been identified in 
gesho and may be responsible for its inhibitory effects (74). Despite the many studies that have 
been done using R. prinoides, many more investigations into gesho and gesho-derived compounds 
remain to be conducted.       
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1.3.1 What is gesho? 
Rhamnus prinoides, a large evergreen shrub native to East Africa, is used in the production 
of two popular, traditional alcoholic beverages called tella and te’j (75). In beverage production, 
gesho is used as a bittering agent similar to hops in Western beer (76). The processes used for 
brewing tella and te’j consist of multiple stages and vary from person to person but several steps 
are conserved (77). The process begins with the smoking of clay pots for seasoning and 
sterilization (76–78). Gesho leaves or stems are then added to water in the pot and allowed to 
ferment for several days (76–78). When producing te’j, raw honey or sugar is added to the mixture 
while grains such as barley and malt are added when brewing tella (76, 77). Both drinks are 
allowed to ferment for 15-20 days or until the alcohol content reaches between 2-8% (76, 78). 
Despite the commercial production of te’j, the traditional origins of both tella and te’j have resulted 
in a variety of recipes as the instructions have been altered and passed down the generations (77). 
1.3.2 Applications in traditional medicine 
In addition to uses as a bittering agent in beverage production, gesho has also been used 
traditionally to treat a variety of illnesses. Aqueous tinctures containing gesho have been used for 
the treatment of arthritis, back pain, brucellosis, flu, common cold, indigestion, loss of appetite, 
pneumonia, fatigue, sexually transmitted diseases, stomach ache and ear nose and throat infections 
(79, 80). R. prinoides leaves have also been ground and mixed with butter to be used as an ointment 
for the treatment of eczema (81). In an attempt to validate or refute some of the acclaimed 
medicinal uses of gesho, researchers began investigating the plant for antibacterial and 
antiplasmodial activities. Researchers in Japan found that R. prinoides methanol extracts were 
effective at killing plasmodia both in vitro and in vivo, with decreased parasitemia and prolonged 
survival in mice treated with gesho extract compared to untreated control mice (82, 83). Gesho has 
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also been found to have biocidal activity against both Gram positive and Gram negative species of 
bacteria in planktonic culture (75, 84, 85). Despite the research that has been done on the 
antimicrobial and antiplasmodial activities of gesho, nothing is known about its effects on bacterial 
biofilms, this dissertation looks to help fill this gap in knowledge. 
 
1.4 Hypothesis and objectives  
The overall hypothesis of this work is Rhamnus prinoides (gesho) extracts and derived 
compounds exhibit anti-biofilm activity against Gram positive bacteria and yeast. To test this 
hypothesis, the following objectives were proposed: 
1.4.1 Aim 1: Screen gesho extracts for anti-biofilm activity and identify active 
compounds 
Four extracts were prepared from the leaves and stems of gesho and screened for anti-
biofilm activity. 96-well microtiter plate, crystal violet assay were used to assess the effects of the 
extracts on biofilm formation. Resting cell viability counts were performed in order to determine 
if biofilm prevention was due to a biocidal, bacteriostatic or anti-pathogenic mechanism. Of the 
extracts tested, the leaf ethanol extract was selected for chemical analysis to identify individual 
compounds with anti-biofilm activity. 
1.4.2 Aim 2: Evaluate the effects of gesho ethanol extracts on dual-species biofilms 
Gesho ethanol extracts were screened for anti-biofilm activity against Streptococcus 
mutans and Candida albicans mono- and dual-species biofilms. 96-well microtiter plate, crystal 
violet assays were used to assess the effects on biofilm formation while resazurin assays were used 
to assess anti-microbial activity on biofilm dwelling cells. Growth curve experiments were 
conducted to characterize the anti-biofilm activity of the stem ethanol extract as biocidal, 
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bacteriostatic or anti-pathogenic. Finally, the effect of the stem ethanol extract on extracellular 
polysaccharide production was assessed to identify a potential mechanism for biofilm inhibition. 
1.4.3 Aim 3: Identify benzoic compounds with anti-pathogenic anti-biofilm activity 
and characterize their phenotypic effects 
Benzoic compounds with structural similarity to the gesho-derived ethyl 4-ethoxybonzic 
acid were screen for anti-pathogenic anti-biofilm activity on Staphylococcus aureus. Three target 
compounds were identified and their effects on planktonic growth and antibiotic sensitization were 
evaluated. Phenotypic assays were used to characterize the effects of treatment on cell 
hydrophobicity, hemolysis activity, membrane permeability and EPS production.  
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2 RHAMNUS PRINOIDES (GESHO): A SOURCE OF DIVERSE ANTI-MICROBIAL 
ACTIVITY  
2.1 Introduction 
Microbial biofilms, or surface-attached communities of microorganisms, are a source of 
chronic infection. In contemporary medicine, concern over biofilms is frequently elicited by 
numerous conditions, including device-related infections and chronic wounds (42, 47, 86). A wide 
range of pathogenic bacteria are reported to establish biofilm infections (87, 88). These include 
Staphylococcus aureus and Streptococcus mutans, two opportunistic pathogens whose biofilms 
are responsible for diseases including endocarditis and tooth decay, respectively (45, 89). In 
traditional settings, biofilm-associated infections would most commonly be encountered in 
wounds, on the skin and in the mouth. The severity of biofilm infections in combination with the 
increased prevalence of antibiotic resistance, has led to an ethnopharmacological approach to 
finding novel anti-biofilm agents (40, 90).  
Rhamnus prinoides (gesho) is a large evergreen shrub native to East Africa that is used as 
a bittering agent in the traditional East African fermented beverages tella and tej (77, 91). In 
addition to its culinary use, gesho has been used historically as a treatment for a variety of illnesses. 
Aqueous tinctures containing gesho have been used for the treatment of arthritis, back pain, 
brucellosis, flu, common cold, indigestion, loss of appetite, pneumonia, fatigue, sexually 
transmitted diseases, stomach ache and ear, nose and throat infections (79, 80). Notably, a mixture 
of ground R. prinoides leaves and butter has been used as an ointment for the treatment of atopic 
dermatitis (81), a skin condition occasionally associated with Staphylococcus aureus infections 
(92). Gesho contains a complex mixture of potentially therapeutic biocidal chemicals active 
against planktonic pathogens, notably geshoidin, quercetin, emodin, and various anthracene 
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derivatives  (74, 85, 93). Based on this background information, we hypothesized that gesho could 
be a source of anti-biofilm compounds effective against S. aureus and other Gram positive 
bacteria. Additionally, we sought anti-biofilm compounds with low biocidal activity; i.e. that had 
anti-pathogenic properties (64, 65). 
2.2 Materials and Methods 
2.2.1 Bacterial strains and culture conditions 
Four species of microorganisms were employed in this work: Staphylococcus aureus 
ATCC 6538, Bacillus subtilis ATCC 23059, Pseudomonas aeruginosa PA01 and Streptococcus 
mutans. Streptococcus mutans was a gift from Margaret Gould-Bartlett, Georgia State University. 
Pseudomonas aeruginosa PA01 was obtained from the laboratory of Jay Keasling, University of 
California, Berkeley. S. aureus was grown in Luria-Bertani (LB) broth (Becton Dickinson, USA). 
B. subtilis was cultivated in LB broth supplemented with 150 mM ammonium sulfate, 100 mM 
potassium phosphate, 34 mM sodium citrate, 1 mM MgSO4 and 0.1% glucose (94). S. mutans was 
grown in Brain-Heart Infusion (BHI) medium (Becton, Dickinson, USA) supplemented with 0.5% 
sucrose. P. aeruginosa was cultivated in Pseudomonas basal mineral (PBM) medium containing 
80 mM glucose (60). 
2.2.2 Chemicals and reagents 
The following reagents were purchased from Fisher Scientific (USA): crystal violet, 
potassium phosphate, magnesium sulfate, ammonium sulfate, hexanes, methanol, and sodium 
carbonate. Reagents purchased from Sigma Aldrich (USA) include: sucrose, butanol, Folin-
Ciocalteu reagent, ninhydrin reagent, sodium bicarbonate, cupric sulfate. Sodium citrate, glucose 
and ethyl acetate were purchased from EM Science (USA), OmniPur (Germany) and Pharmco-
Aaper (USA), respectively. 95% ethanol was purchased from Decon Labs (USA). 
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2.2.3 Extract preparation 
Rhamnus prinoides stems and leaves were purchased from a local Ethiopian market 
(Buford, Georgia, USA). The authenticity of the stems and leaves was verified by two local experts 
on Ethiopian foods. 24 g of ground leaves or fractured stems were added to 150 ml of sterile water 
or 95% ethanol in a 250 ml flask (95, 96). Flasks were shaken in the absence of light at 200 rpm 
at room temperature for four days. The extraction liquid was then collected and particulate matter 
removed via centrifugation at 12,500 rpm at 4 °C for 5 min; clarified supernatants were recovered 
for further processing. Aqueous extracts were frozen at -80 °C and lyophilized (Virtis, USA) to 
remove all water. Ethanol extracts were air-dried under vacuum prior to lyophilization. Extracts 
were stored at -80 °C. The percent yield (w/w) of the leaf ethanol, leaf water, stem ethanol and 
stem water extracts were: 8, 13, 2 and 7%, respectively.  
2.2.4 Log-phase cell antibacterial assay  
Bacteria were inoculated in 20 ml of growth media at an initial optical density (OD600) of 
0.01 and incubated for 4 ± 1 h at 37 °C with shaking at 200 rpm until log phase (OD600 ≈ 0.35) was 
reached. 1 ml of log-phase cells was transferred to 1.5 ml microfuge tubes and the growth medium 
was removed via centrifugation. Pelleted cells were washed twice with phosphate buffered saline 
(PBS) before resuspending the pellets in 1 ml of extract dissolved in PBS. Extract concentrations 
ranged from 2.5 – 10 mg/ml and were selected following a preliminary activity screen using S. 
aureus and then used for each of the other tested species. Treatments were incubated at 37 °C for 
1 h and then serially diluted in PBS and radially plated on growth agar. Plate counts were used to 
assess biocidal activity. 
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2.2.5 Stationary-phase cell viability assay  
To assess the viability of stationary phase planktonic cells, a growth agar-based assay was 
conducted. Spent media containing stationary phase planktonic cells were collected from 
microtiter plates or borosilicate glass culture tubes after the conclusion of each biofilm formation 
assay. The collected cells were serially diluted (1:10) in PBS and dilutions were radially plated in 
10 µl volumes on growth medium. Agar plates were incubated at 37 °C overnight to allow for 
colony formation and plate counts were used to assess viability. 
2.2.6 Staphylococcus aureus, Streptococcus mutans and Pseudomonas aeruginosa 
biofilm formation assay 
Staphylococcus aureus, Streptococcus mutans and Pseudomonas aeruginosa biofilms were 
grown in LB broth, BHI medium containing sucrose and PBM-glucose, respectively. Biofilm 
formation was assessed using a polystyrene 96 well microtiter plate crystal violet assay (97). 
Overnight broth cultures were diluted to an initial OD600 of 0.01 in fresh media and combined with 
gesho extract to obtain a final concentration of 7 mg/ml. Treatments were then serially diluted to 
final extract concentrations of 5, 3, 1, 0.5 and 0.25 mg/ml. These concentrations were selected 
after preliminary screens of the four extracts using S. aureus and were then used for each of the 
additional species that were examined. No vehicles were added to solubilize the treatments. 
Negative controls consisted of cells diluted to an initial OD600 of 0.01 in growth media without 
plant extract. 100 µl of treated and untreated samples were added to each well of a microtiter plate 
and incubated at 37 °C for 24 h (98, 99). After 24 h, planktonic cells and spent growth media were 
removed from each well and the plate was washed 3 times in sterile water. Biofilms were then 
stained with 150 µl of 0.1% crystal violet for 15 min at 200 rpm. Excess dye was removed via 
washing in sterile water and the plate was allowed to air dry. Crystal violet was solubilized in 150 
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µl of 95% ethanol and absorbance measurements at 595 nm were taken using an MD 
SPECTRAmax plate reader (Molecular Devices Corporation, USA). 
2.2.7 Bacillus subtilis biofilm formation assay  
Bacillus subtilis biofilms were grown in LB broth supplemented with 150 mM ammonium 
sulfate, 100 mM potassium phosphate, 34 mM sodium citrate, 1 mM MgSO4 and 0.1% glucose 
(94). Overnight broth cultures were diluted to an initial OD600 of 0.01 in fresh supplemented LB 
media and combined with gesho extract to obtain a final concentration of 7 mg/ml. Treatments 
were then serially diluted to final concentrations of 5, 3, 1, 0.5 and 0.25 mg/ml. No vehicles were 
added to solubilize the treatments. Negative controls consisted of cells diluted to an initial OD600 
of 0.01 in growth media without plant extract. 1 ml of treated and untreated samples were added 
to sterile 10 ml borosilicate glass culture tubes and statically incubated at 30 °C for 48 h to allow 
for pellicle formation. After 2 days, planktonic cells and spent growth media were removed from 
below the pellicle that formed at the air to liquid interface. Pellicles were vortexed and pipetted 
for resuspension in 1 ml PBS then serially diluted (1:10) in PBS and radially plated on LB agar 
plates. Agar plates were incubated at 37 °C overnight to allow for colony formation and plate 
counts were used to quantify the number of biofilm cells. Bacillus subtilis biofilms were cultivated 
in glass test tubes due to a lack of robust biofilm formation in polystyrene microtiter plates. 
2.2.8 Pure compounds on Staphylococcus aureus and Pseudomonas aeruginosa 
biofilm formation assay 
Staphylococcus aureus and Pseudomonas aeruginosa biofilms were grown in LB broth 
and PBM-glucose, respectively. Biofilm formation was assessed using a polystyrene 96 well 
microtiter plate crystal violet assay (97). Overnight broth cultures were diluted to an initial OD600 
of 0.01 in fresh media and combined with pure compounds to obtain a final concentration of 6.2% 
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(v/v). Treatments were then serially diluted to final concentrations of 3.1, 1.7, 0.8 and 0.4% (v/v). 
DMSO was added to solubilize the treatments. Negative controls consisted of cells diluted to an 
initial OD600 of 0.01 in growth media without treatment. 100 µl of treated and untreated samples 
were added to each well of a microtiter plate and incubated at 37 °C for 24 h. After 24 h, planktonic 
cells and spent growth media were removed from each well and the plate was washed 3 times in 
sterile water. Biofilms were then stained with 150 µl of 0.1% crystal violet for 15 min at 200 rpm. 
Excess dye was removed via washing in sterile water and the plate was allowed to air dry. Crystal 
violet was solubilized in 150 µl of 95% ethanol and absorbance measurements at 595 nm were 
taken using an MD SPECTRAmax plate reader (Molecular Devices Corporation, USA). 
2.2.9 Liquid to liquid extraction  
The fractionation strategy employed in this work followed the approach described by 
Quave et al., 2012 (100). Liquid to liquid extraction was conducted to separate the various 
components of the gesho leaf ethanol extract. A 1:1 ratio of water and hexanes was added to a 
separatory funnel. 500 mg of gesho leaf ethanol extract were solubilized in 10 ml of 95% ethanol 
was added to the separatory funnel. Solvents were thoroughly mixed via inversion and then 
allowed to separate before fraction collection in 250 ml Erlenmeyer flasks. Aqueous fractions were 
reintroduced to the separatory funnel and an additional 10 ml hexanes were added. Solvents were 
mixed via inversion and allowed to separate for fraction collection. A final hexane separation was 
conducted using an additional 10 ml of hexane. Subsequent extractions were performed with 
water-saturated butanol and ethyl acetate following the aforementioned method. Subsequently all 
fractions were dried under air to remove solvents, re-suspended in water and lyophilized.  
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2.2.10 Low Pressure Liquid Chromatography (LPLC) 
LPLC was performed using Bondapack C18/ Corasil as the stationary phase. 10 mg and 7 
mg of the butanol and ethyl acetate residual compounds, respectively, were dissolved in 1 ml of 
ethanol and applied to the column. Gradient separations were performed by changing mobile phase 
at 10% intervals from 100% methanol to 100% water. Eluted fractions were collected in 
polystyrene culture tubes at 5 ml intervals and stored at 4 °C.  
2.2.11 Chemical tests 
Chemical tests were used to help identify the chemical components present in R. prinoides 
ethanol extracts. Ninhydrin (101), Folin-Ciocalteu (102), Baeyer (103), Jones Oxidation (104), 
carboxylic acid (105) and Biuret tests (106) were conducted according to standard protocols with 
the following modifications:  Ninhydrin test: instead of spraying chromatography paper with the 
ninhydrin reagent, 10 µl drops of ninhydrin reagent were applied directly to spots of dried sample. 
Folin-Ciocalteu test: volumes were modified to allow this assay to be performed in a microtiter 
plate rather than a cuvette; 18 µl of sample, 36 µl of Folin-Ciocalteu reagent and 145 µl of 20% 
sodium carbonate were used. Baeyer test: 1 drop of each sample was dissolved in 500 µl of acetone. 
Jones Oxidation: 5 drops of acetone and chromate solution were used to dissolve 4 drops of each 
sample. Carboxylic acid test: 1 ml of 100 mg/ml sodium bicarbonate solution was added to 3 drops 
of each sample.  Biuret test: a 25 mg/ml cupric sulfate solution was used for analysis. 
2.2.12 Gas chromatography-mass spectrometry (GC-MS) 
Gas chromatography-mass spectrometry (GC-MS) analysis was performed using an 
Agilent Technology 7890A gas chromatograph equipped with an Agilent Technology 5977A mass 
spectrometer. A sample volume of 5 µL was manually injected into an Agilent (30 m, 0.530 mm) 
HP-5MS column. The oven temperature was held at 60 °C for 5 min, then was raised to 100 °C at 
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25 °C/min. The temperature was stabilized at 100 °C for 1 min then raised to 200 °C at 25 °C/min 
and held at 200 °C for 1 min. Temperature was raised to 250 °C at a rate of 5 °C/min then held at 
the final baking temperature of 250 °C for 7 min. Agilent MassHunter software was used for mass 
spectrometry data acquisition and analysis.  
2.2.13 Fourier Transform Infrared Spectroscopy (FTIR) 
A Varian UMA 600 FTIR microscope equipped with He-Ne laser and MCT detector was 
used for analysis. 3 µL of select LPLC fractions were vacuum desiccated onto zinc solenoid 
windows. Data were collected in the 3750–925 cm-1 region at a 4 cm-1 spectral resolution.  
2.2.14 Statistical Analysis 
Statistical analysis was performed using IBM SPSS Statistics 22.0 software. Non-parametric 
(Kuskal-Wallis Test and Median Test) or parametric (ANOVA followed by Tukey HSD test or t-
test) analyses of variance were conducted based on the characteristics of the data. Comparisons 
were conducted between the extract treated samples and the untreated control. Differences with a 
p-value < 0.05 were considered statistically significant and are designated with an asterisk (*).     
2.3 Results and Discussion 
2.3.1 Gesho ethanol extracts have biocidal activity against log phase planktonic cells 
Ethanol and aqueous extracts of gesho were tested for their ability to kill log-phase, 
planktonic cells of Staphylococcus aureus, Streptococcus mutans and Bacillus subtilis. Ethanol 
extract treatments resulted in a 2 to 10 log reduction in colony forming units (CFU) per ml, whereas 
aqueous extract treatments resulted in a 1 to 3 log reduction in CFU per ml (Figure 1). Both stem 
and leaf ethanol extracts exhibited significant biocidal activity against all three species tested. The 
aqueous extracts exhibited greater variability; in particular, aqueous stem extract was active 
against S. aureus and B. subtilis but not S. mutans. The strong biocidal activity of the ethanol 
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extracts and lower activity of the aqueous extracts were consistent with the findings of Molla et 
al., 2016 who reported MICs for gesho extracts from 2 to 8 mg/mL; but greater than Amabye, 2015 
at 0.2 to 0.4 mg/mL and less than Berhanu, 2014 who reported active concentrations ranging from 
97.5 to 780 mg/mL (75, 84, 85).  
2.3.2 Gesho ethanol extracts influence the growth of stationary phase cells 
Gesho ethanol extracts exhibited biocidal or bacteriostatic activity against stationary phase 
cells. The number of viable cells present in the inocula, indicated by a dotted red line, were 
quantified to allow for comparisons of growth relative to starting conditions (Figure 2). Treatments 
of B. subtilis or S. mutans with stem ethanol extract resulted in a decrease in biomass when 
compared to the untreated inoculum, signifying biocidal activity. Stem ethanol treatment of S. 
aureus and leaf ethanol treatments of S. mutans and B. subtilis exhibited a bacteriostatic effect, 
showing little change in cell number compared to the inocula. Leaf ethanol extract impaired S. 
aureus growth in comparison to growth of the untreated control, possibly due to slight bactericidal 
activity or toxicity of the treatment. The variability of these findings suggests that the gesho ethanol 
extracts contain a mixture of chemicals that impact Gram positive bacteria in a species specific 
manner. Overall, these findings indicated that the stem ethanol extract was a good source of 
biocidal, anti-biofilm compounds, whereas the leaf ethanol extract was a good source of non-
biocidal antibacterial (i.e. anti-pathogenic) compounds. Due to the superior inhibition of biofilm 
formation caused by the ethanol extracts, we elected not to assess the activity of the aqueous 
extracts on stationary phase cells (Figure 3). 
2.3.3 Gesho ethanol extracts prevent Gram positive bacterial biofilm formation    
Gesho ethanol extracts strongly inhibited Gram positive bacterial biofilm formation. Both 
ethanol stem and leaf extracts significantly inhibited S. aureus, S. mutans and B. subtilis biofilm 
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formation up to 99% relative to untreated control biofilms (Figure 3). The extent of inhibition was 
species dependent with S. aureus showing less susceptibility to treatment than B. subtilis and S. 
mutans. Aqueous extracts inhibited S. aureus and S. mutans biofilms but increased B. subtilis 
biofilm formation. B. subtilis biofilm formation may have been stimulated by the presence of 
polysaccharides (107) or peptides with pheromone-like activity (108) in the extract; these 
hypotheses have not yet been tested. As noted above, the effects of aqueous extracts were more 
variable in activity, resulting in inhibition of S. aureus and S. mutans but not B. subtilis biofilms. 
Stem extracts generally resulted in greater biofilm inhibition than their leaf counterparts, 
suggesting a difference in chemical composition between the two tissues. All extracts were 
ineffective at disrupting existing biofilms or inhibiting Gram negative bacterial biofilm formation 
(Figure 4). 
2.3.4 Gesho-derived small molecules inhibit Gram positive biofilm formation  
Further work on the leaf ethanol extract was pursued because the data in Figures 2 and 3 
indicated that compounds contained within prevented biofilm formation with minimal bactericidal 
activity. Liquid to liquid fractionation was used to separate the extract on the basis of polarity, 
followed by chemical tests, Fourier Transform infrared spectroscopy (FTIR) and gas 
chromatography-mass spectrometry (GC-MS) (Figure 5).  
Low pressure liquid chromatography of the butanol and ethyl acetate liquid to liquid 
fractions indicated that the most effective compounds were present in the more polar liquid phases 
(Figure 6). Colorimetric chemical tests indicated the presence of polyphenolic and alcoholic 
compounds (Table 1). FTIR supported these findings, showing a strong hydroxyl peak and several 
alkyl or alkene peaks (Figure 7). 
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GC-MS analysis found numerous peaks within the butanol fraction (Figure 8); compound 
identities were determined using the NIST11 chemical library. Compounds resulting in a certainty 
score greater than 85% were selected for further analysis. Activity screens identified two 
compounds with anti-biofilm activity: ethyl 4-ethoxybenzoate (CAS# 23676-09-7) and 4-hydroxy-
4-methyl pentanone (CAS# 123-42-2) (Figure 8). Ethyl 4-ethoxybenzoate (EEB) and 4-hydroxy-
4-methyl pentanone (HMP) are naturally occurring compounds that have been previously been 
extracted from plants (109–112). 4-hydroxy-4-methyl pentanone, also known as diacetone alcohol 
(DAA), is commonly used as an industrial solvent; however, HMP was not used as a solvent in 
this study, suggesting that it occurs naturally in gesho. Benzoic acid and 2-pentanone, compounds 
that are structurally similar to EEB and HMP respectively, were evaluated for anti-biofilm activity 
at 0.8% and 3%. Neither benzoic acid nor 2-pentanone had a statistically significant effect on 
biofilm formation. These data support the concept that the observed anti-biofilm activity of EEB 
and HMP was caused by their chemical structures rather than by non-specific effects.  
A major peak in the butanol fraction was identified as dimethyl sulfoxide (DMSO). DMSO 
is commonly used in laboratories as a solvent, but, in this study, it was a component of the GC-
MS output (Figure 8). We considered several hypotheses to explain its presence. First, we analyzed 
all of the solvents used in this work to determine whether it was a contaminant. GC-MS analyses 
indicated that it was not found in the solvents (data not shown). Second, we considered whether it 
could be a natural product; however, we could not find any published reports that support this idea. 
Lastly, we hypothesized that DMSO could be a rearrangement product that formed as an artifact 
during GC-MS analysis (113). Regardless, we hypothesized that the presence of DMSO increased 
the anti-biofilm activity of EEB by increasing its solubility; this idea was supported by laboratory 
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experiments (Figure 9A). DMSO was combined with HMP to assess if DMSO would result in 
enhanced anti-biofilm activity as occurred with EEB, but DMSO did not enhance HMP activity.   
EEB and HMP treatments exhibited significant anti-biofilm activity but did not show 
antibacterial activity against log or stationary phase cells; these are hallmark characteristics of 
“anti-pathogenic” compounds (Figure 9 C-F). Anti-pathogenic therapeutics are compounds that 
target microbial pathogenicity while minimizing bactericidal activity (65). Anti-pathogenic and 
antivirulence compounds have gained attention in recent years because they apply less selective 
pressure against pathogens than bactericidal agents; these compounds may also delay the 
development of antibiotic resistance or restore sensitivity to antibiotic resistant, pathogenic strains 
(64, 65, 114). The anti-biofilm activity of HMP may derive from its structural similarity to 
autoinducer-2 (AI-2), a quorum sensing signaling molecule that affects diverse bacterial 
phenotypes including biofilm formation (115, 116). HMP may act as a competitive inhibitor of 
AI-2 signaling. Notably, HMP inhibited biofilm formation by P. aeruginosa PA01, although this 
activity was not observed with the crude gesho extracts (Figure 10). The mode of action behind 
the anti-biofilm activity of EEB is unknown, but its structural similarity to parabens suggest that 
it may influence biofilm formation through a common mechanism (117, 118).  
There are several novel features in the presented work. This is the first research project to 
focus on gesho for its anti-biofilm activity. This work complements existing findings on the 
antibacterial (75, 85) and anti-parasitic (82, 83, 119) properties of gesho. Second, the extracts used 
in this research were unique compared to those used in prior works; they were prepared using 
ethanol rather than methanol in an effort to extract chemical compounds that were likely to be 
present in traditional brews and tinctures (76, 78). Third, this project tested both leaf and stem 
extracts independently for antibacterial and anti-biofilm activity, which proved informative as their 
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characteristics and efficacies were different. Overall, our findings support the traditional use of 
gesho for health benefits and also indicate that gesho-derived compounds could potentially have 
applications as therapeutics and as hygiene products. 
2.4 Conclusion 
Biofilm formation is a complex process, involving cells that switch from a planktonic to a 
sessile phenotype. The change to a surface-attached mode of growth may be induced by 
environmental cues or by signals produced by neighboring cells. Accordingly, there is a large 
network of genes involved with attachment. Moreover, the components involved in biofilm 
formation can vary greatly as microbes from diverse genera seek the benefits of a biofilm lifestyle. 
From a therapeutic perspective, this means that there are many targets by which to influence 
microbial biofilm formation.  
Numerous anti-biofilm, anti-pathogenic and antivirulence compounds have been identified 
in plant essential oils (59, 61, 63, 120). Gesho, like other plant essential oils, is a mixture of diverse 
chemicals (74, 85). It is likely that some of the observed variation in gesho extract-induced activity 
is the result of different molecules contained therein affecting biofilm formation through diverse 
mechanisms. In this work we report two specific compounds with anti-biofilm activity derived 
from gesho. We predict that investigating additional constituents of gesho extracts will yield more 
novel molecules with anti-biofilm activity. 
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2.5 Figures and Tables 
 
 
Figure 1. Bactericidal effect of aqueous and ethanol extracts on log-phase, planktonic cells. 
(A-D) Staphylococcus aureus (n = 3-6); (E-H) Bacillus subtilis (n = 3-4) and (I-L) Streptococcus 
mutans (n = 3-4). Bars indicate number of bacteria present in culture following exposure to extracts 
for 1 h. Legend: leaf ethanol (white bars), leaf aqueous (horizontal striped bars), stem ethanol (grey 
bars), stem aqueous (slanted striped bars). Error bars are standard error of the mean. ANOVA and 
Kruskal-Wallis tests were performed; (*) indicates a significant difference (p < 0.05) between 
treated samples and the untreated control. 
 
 
 
 
 
 
         
         
       
Figure 1. Bactericidal effect of aqueous and ethanol extracts on log-phase, planktonic cells. 
(A-D) Staphylococcus aureus (n = 3-6); (E-H) Bacillus subtilis (n = 3-4) and (I-L) Streptococcus 
mutans (n = 3-4). Bars indicate number of bacteri  present in culture following exposure to extracts 
for 1 h. Legend: leaf eth nol (white bars), leaf aqueous (horizonta  st iped bars), stem ethanol (grey 
bars), stem aqu ous (slanted striped bars). Error bars are standard error of the mean. ANOVA d 
Kruskal-Wallis tests were performed; (*) indicates a significant difference (p < 0.05) between 
treated samples and the untreated control. 
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Figure 2.Effect of ethanol extracts on resting phase planktonic cell viability. 
(A-B) Staphylococcus aureus (n = 3), (C-D) Bacillus subtilis (n = 3-4), (E-F) Streptococcus mutans 
(n = 3). Bars indicate the number of viable cells after growth for 24 h in the presence of stem (light 
grey bars) and leaf (white bars) ethanol extracts. Black bars represent untreated controls. The 
inoculum cell density is indicated by a red dotted line. Error bars are standard error of the mean.  
ANOVA, T-test, Kruskal-Wallis tests were performed; (*) indicates a significant difference (p < 
0.05) between treated samples and the untreated control. 
 
 
 
 
 
 
 
 
 
        
 
    
          
Figure 2. Effect of ethanol extracts on resting phase planktonic cell viability. (A-B) 
Staphylococcus aureus (n = 3), (C-D) Bacillus subtilis (n = 3-4), (E-F) Streptococcus mutans (n = 
3). Bars indicate the number of viable cells after growth for 24 h in the presence of stem (light 
grey bars) a  le f (w ite bars) thanol extracts. Black bars represent untreated controls. The 
inoculum cell density is indicated by a red dotted line. Error bars are standard error of the mean.  
ANOVA, T-test, Kruskal-Wallis tests were performed; (*) indicates a significant difference (p < 
0.05) between treated samples and the untreated control. 
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Figure 3. Effect of aqueous and ethanol extracts on Gram positive bacterial biofilm formation. 
(A-D) Staphylococcus aureus (n=10-15), (E-H) Bacillus subtilis (n=3-4) and (I-L) Streptococcus 
mutans (n=12). Bars indicate the extent of biofilm formation relative to untreated controls. Legend: 
leaf ethanol (white bars), leaf aqueous (horizontal striped bars), stem ethanol (grey bars), stem 
aqueous (slanted striped bars). Error bars are standard error of the mean. ANOVA and Kruskal-
Wallis tests were performed; (*) indicates a significant difference (p < 0.05) between treated 
samples and the untreated control.  
 
 
 
 
 
 
 
 
         
       
      
       
 
Figure 3. Effect of aqueous and ethanol extracts on Gram positive bacterial biofilm 
formation. (A-D) Staphylococcus aureus (n=10-15), (E-H) Bacillus subtilis (n=3-4) and (I-L) 
Streptococcus mutans (n=12). Bars indicate the extent of biofilm formation relative to untreated 
controls. Legend: le f e anol (white ars), lea  aqueous (horizontal striped bars), stem ethanol 
(grey bars), stem aqueous (slanted striped bars). Error bars are standard error of the mean. ANOVA 
and Kruskal-Wallis tests were performed; (*) indicates a significant difference (p < 0.05) between 
treated samples and the untreated control.  
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Figure 4. Effect of aqueous and ethanol extracts on Pseudomonas aeruginosa biofilm formation. 
Bars indicate the extent of biofilm formation relative to untreated controls. Legend: leaf ethanol 
(white bars), leaf aqueous (horizontal striped bars), stem ethanol (grey bars), stem aqueous (slanted 
striped bars). Error bars are standard error of the mean. Kruskal-Wallis tests were performed; (*) 
indicates a significant difference (p < 0.05) between treated samples and the untreated control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
Supplementary Figure 1. Effect of aqueous and ethanol extracts on Pseudomonas aeruginosa 
biofilm formation. Bars indicate the extent of biofilm formation relative to untreated controls. 
Legend: leaf ethanol (white bars), leaf aqueous (horizontal striped bars), stem ethanol (grey bars), 
stem aqueous (slanted striped bars). Error bars are standard error of the mean. Kruskal-Wallis tests 
were performed; (*) indicates a significant difference (p < 0.05) between treated samples and the 
untreated control. 
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Figure 5.Diagram of gesho leaf ethanol extract fractionation and chemical analysis. 
Crude ethanol extracts were prepared from ground leaves of R. prinoides, followed by liquid to 
liquid fractionation using hexanes, butanol and ethyl acetate. Butanol and ethyl acetate fractions 
were further separated via column chromatography and then analyzed via colorometric chemical 
tests, Fourier transform infrared spectroscopy and gas chromatography-mass spectrometry 
(GCMS). Chemical compounds identified via GCMS were screened for antimicrobial and anti-
biofilm activity.  
 
 
 
 
 
 
 
 
 
Figure 4. Diagram of gesho leaf ethanol extract fractionation and chemical analysis. 
Crude ethanol extracts were prepared from ground leaves of R. prinoides, followed by liquid 
to liquid fractionation using hexanes, butanol and ethyl acetate. Butanol and ethyl acetate 
fractions were further separa ed vi  column chromatography and then an lyzed vi  
colorometric chemical tests, Fourier transform infrared spectroscopy and gas 
chromatography-mass spectrometry (GCMS). Chemical compounds identified via GCMS 
were screened for antimicrobial an  anti-biofilm activity.  
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Figure 6. Effect of low pressure liquid chromatography fractions on Staphylococcus aureus 
biofilm formation. 
Bars indicate the extent of biofilm formation relative to untreated controls. Legend: further 
separation of the butanol liquid to liquid fraction (grey bars), further separation of the ethyl acetate 
liquid to liquid fraction (white bars). Error bars are standard error of the mean. 
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Legend: further separation of the butan l liquid to liquid fraction (gr y bars), further separation of 
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Table 1. Chemical tests indicate the presence of alcohol- and phenol-containing 
compounds in the butanol and ethyl acetate fractions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemical Test Functional group Test result 
Ninhydrin test   Amines Negative 
Folin-Ciocalteu test Polyphenols Positive 
Beyer/ Potassium permanganate test Alkenes and Alkynes Negative 
Jones Oxidation/ Sodium Chromate test Alcohols Positive 
Carboxylic acid test Carboxylic acid Negative 
Biuret test Peptide bonds Negative 
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Figure 7. Fourier transform infrared spectroscopy of butanol and ethyl acetate fractions. 
Butanol (A) and ethyl acetate (B) fractions prepared on May 26th, 2017 (black) and June 15th, 2017 
(red) exhibit strong hydroxyl (blue box), alkane (green box) and alkene (yellow and grey box) 
peaks. Peak strength was 4-5 times stronger in the butanol fraction chromatogram than the ethyl 
acetate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Fourier transform infrared spectroscopy of butanol and ethyl 
acetate fractions. Butanol (A) and ethyl acetate (B) fractions prepared on May 26th, 2017 (black) 
and June 15th, 2017 (red) exhibit strong hydroxyl (blue box), alkane (green box) and alkene (yellow 
and grey box) peaks. Peak strength was 4-5 times stronger in the buta ol fracti n chromatogram 
than the ethyl acetate.  
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Figure 8. Gas chromatography mass spectrometry analysis of butanol fraction. 
4-hydroxy-4-methyl-2-pentanone (A, C and E) and Ethyl 4-ethoxybenzoate (B, D and F) were 
identified as compounds present in the butanol fraction. There are numerous additional peaks in 
the mixture whose identities were not resolved or evaluated for antimicrobial or anti-biofilm 
activity. 
     
 
 
 
      
 
Figure 7. Gas chromatography mass spectrometry analysis of butanol fraction. 4-hydroxy-4-
methyl-2-pentanone (A, C and E) and Ethyl 4-ethoxybenzoate (B, D and F) were identified as 
compounds present in the butanol fraction. There are numerous additional peaks in the mixture 
whose identities were not r solved or evaluated for antimicrobial or anti-biofilm activity.    
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Figure 9. Effects of ethyl 4-ethoxybenzoate and 4-hydroxy-4-methyl-2-pentanone on S. aureus 
biofilm formation and planktonic cell viability. 
Top row, effect on biofilm formation. Middle row, effect on resting phase cell viability. Bottom 
row, effect on log phase cell viability. Bars indicate the impact of treatments after 24 h. Legend: 
ethyl 4-ethoxybenzoate (EEB) and 4-hydroxy-4-methyl-2-pentanone (HMP) with (white bars) or 
without (black bars) the presence of 1% DMSO. Each assay was performed in triplicate and error 
bars represent the standard error of the mean.  An ANOVA test was performed; (*) indicates a 
significant difference of (p < 0.05) between the treated samples and the untreated control. 
 
 
 
 
 
       
       
        
 
Figure 8. Effects of ethyl 4-ethoxybenzoate and 4-hydroxy-4-methyl-2-pentanone on S. 
aureus biofilm formation and planktonic cell viability. Top row, effect on biofilm formation. 
Middle row, effect on resting phase cell viability. Bottom row, effect on log phase cell viability. 
Bars indicate the impact of treatments after 24 h. Legend: ethyl 4-ethoxybenzoate (EEB) and 4-
hydroxy-4-methyl-2-pentanone (HMP) with (white bars) or without (black bars) the presence of 
1% DMSO. Each assay was performed in triplicate and error bars represent the standard error of 
the mean.  An ANOVA test was performed; (*) indicates a significant difference of (p < 0.05) 
between the treated samples and the untreated control. 
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Figure 10. Effect of ethyl 4-ethoxybenzoate and 4-hydroxy-4-methyl-2-pentanone on 
Pseudomonas aeruginosa biofilm formation. 
Bars indicate the extent of biofilm formation relative to untreated controls. Error bars are standard 
error of the mean. Kruskal-Wallis tests were performed; (*) indicates a significant difference (p < 
0.05) between treated samples and the untreated control. 
 
 
 
  
 
 
 
              
 
Supplementary Figure 3. Effect of ethyl 4-ethoxybenzoate and 4-hydroxy-4-methyl-2-
pentanone on Pseudomonas aeruginosa biofilm formation. Bars indicate the extent of biofilm 
formation relative to untreated controls. Error bars are standard error of the mean. Kruskal-Wallis 
tests were performed; (*) indicates a significant difference (p < 0.05) between treated samples and 
the untreated control. 
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3 RHAMNUS PRINOIDES (GESHO) STEM EXTRACT PREVENTS CO-CULTURE 
BIOFILM FORMATION BY STREPTOCOCCUS MUTANS AND CANDIDA 
ALBICANS 
3.1 Introduction 
Streptococcus mutans and Candida albicans form robust polymicrobial biofilms in the oral 
cavity that are associated with a variety of oral and systemic illnesses. Growing alone, 
Streptococcus mutans biofilms are the major etiologic agent of dental caries and tooth decay while 
Candida albicans biofilms can result in oral candidiasis (121, 122). Working together, S. mutans 
and C. albicans dual-species biofilm infections are causal agents of disease including early-
childhood caries, denture stomatitis, periodontitis, candidiasis, endocarditis and mucosal 
infections (123). In dual-species biofilms, these organisms exhibit a symbiotic relationship, 
exchanging metabolites and growth factors to ensure their mutual survival (124); this relationship 
can lead to enhanced biomass, exopolysaccharide production, resistance to stress and virulence 
gene expression (125, 126). This is a major concern as biofilms frequently have enhanced 
resistance to antibiotics, leading to treatment failure (7). In response, researchers have pursued 
plant extracts as a source of anti-biofilm therapeutics. There is a substantial body of research 
investigating the ability of plant extracts to control S. mutans  (127, 128) or C.albicans (129, 130)  
mono-species biofilm; however, considerably fewer studies have focused on these organisms in 
polymicrobial biofilms (127). This is of concern because polymicrobial biofilms are generally 
more difficult to eradicate than their mono-species counterparts (131–133).  
Rhamnus prinoides (gesho) has been used in traditional medicine throughout eastern Africa. 
The fruit, root, stems and leaves of gesho have been historically used to treat a variety of illnesses 
including ear, nose, and throat infections, tonsillitis, scabies, dandruff, rheumatism and pneumonia 
38 
(80, 81). Research on the antimicrobial activities of gesho have shown that extracts possess 
inhibitory activity against a variety of bacteria and plasmodia (75, 119), indicating that gesho is 
effective against both prokaryotes and eukaryotes. Based on this background information, we 
hypothesized that gesho extracts could be used to control Streptococcus mutans and Candida 
albicans biofilms, including co-culture biofilms. 
3.2 Materials and Methods 
3.2.1 Microbial strains and culture conditions 
Streptococcus mutans and Candida albicans were used in this work. Streptococcus mutans 
was a gift from Margaret Gould-Bartlett, Georgia State University and Candida albicans was a 
gift from the laboratory of Sidney Crow, Georgia State University. The S. mutans 16S rDNA and 
16S-23S intergenic spacer sequences were deposited to GenBank (NCBI, USA) under accession 
number MT318140; the GenBank accession number for the C. albicans 18S rDNA-ITS sequence 
was MT166273. The S. mutans and C. albicans strains used in this work shared over 99% 
similarity with the S. mutans T8 and C. albicans ATCC 18804 strains, respectively (Appendix A). 
S. mutans overnight cultures were grown in brain-heart infusion (BHI) (Becton, Dickinson, USA) 
broth while biofilms were formed in BHI broth supplemented with 0.5% sucrose. C. albicans 
overnight cultures were grow in yeast peptone dextrose (YPD) broth while biofilms were formed 
in 1X RPMI 1640 with L-glutamine (Corning, USA) supplemented with 165 mmol l-1 
morpholinepropanesulfonic acid (MOPS). 
3.2.2 Genetic analysis 
Genomic DNA was extracted from overnight cultures of S. mutans and C. albicans using 
a Quick DNA Fungal/Bacterial Miniprep Kit (Zymo Research, USA). Sequencing of the S. mutans 
16S rDNA and 16S-23S intergenic spacer and the C. albicans 18S and ITS regions were conducted 
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using the primers listed in Appendix A. Polymerase chain reactions were conducted using the Taq 
DNA polymerase kit from New England Biolabs Inc. (USA). Thermal cycling conditions for S. 
mutans included: initial denaturation at 95°C for 3 min; 30 cycles of 95°C for 30 sec, 55°C for 30 
sec and 68° for 2 min; and a final extension at 72°C for 5 minutes. C. albicans thermocycler 
parameters included: initial denaturation at 95°C for 3 min; 30 cycles of 95°C for 30 sec, 55°C for 
30 sec and 68° for 2 min 30 sec; and a final extension at 72°C for 5 minutes. Sanger sequencing 
was conducted at the Georgia State University core facility (Atlanta, GA USA) and Genewiz 
(South Plainfield, NJ USA). The resulting genetic sequences were assembled using DNA Baser 
Assembler v.5 (Heracle Biosoft, Arges, Romania). The contigs are found in GenBank under 
accession numbers MT318140 (S. mutans) and MT166273 (C. albicans). 
3.2.3 Chemicals and reagents 
The following reagents were purchased from Fisher Scientific (USA): crystal violet, 
potassium phosphate. Reagents purchased from Sigma Aldrich (USA) include: resazurin and 
sucrose. 95% ethanol was purchased from Decon Labs (USA). 2,3-Bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT) was purchased from Invitrogen (USA) 
and RMPI 1640 with L-glutamine was purchased from Corning (USA). Direct Yellow 96 was 
purchased from AK Scientific.  
3.2.4 Extract preparation 
Rhamnus prinoides stems and leaves were purchased from a local Ethiopian market 
(Buford, Georgia, USA). The authenticity of the stems and leaves was verified by two local experts 
on Ethiopian foods (134). 24 g of ground leaves or fractured stems were added to 150 ml of sterile 
water or 95% ethanol in a 250 ml flask (95, 96). Flasks were shaken in the absence of light at 200 
rpm at room temperature for four days. The extraction liquid was then collected and particulate 
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matter removed via centrifugation at 13,000 x g at 4 °C for 5 min; clarified supernatants were 
recovered for further processing. The extracts were air-dried under vacuum then collected in 50 
ml of water and frozen prior to lyophilization. Extracts were stored at -80 °C. The percent yield 
(w/w) of the leaf and stem ethanol extracts were: 8 and 2%, respectively.  
3.2.5 Streptococcus mutans biofilm formation assay  
In vitro Streptococcus mutans biofilms were grown in filter sterilized BHI broth 
supplemented with 0.5% sucrose (BHI-sucrose). Biofilm formation was assessed using a 
polystyrene 96 well microtiter plate crystal violet assay (97, 98). Overnight broth cultures were 
diluted to an initial OD600 of 0.01 (~ 3.8 x10
6 viable cells per milliliter of culture) in BHI-sucrose 
and combined with gesho extract to a final concentration of 7 mg ml-1.  Treatments were then 
serially diluted to final concentrations of 5, 3, 1, 0.5 and 0.25 mg ml-1. No vehicles were added to 
solubilize the treatments. Negative controls consisted of diluted cells in BHI-sucrose without plant 
extract. 100 µl of treated and untreated samples were added to each well of a microtiter plate and 
incubated at 37 ⁰C, 200 rpm for 24 h (135). The next day, planktonic cells and spent media were 
removed from each well and the 96 well plates were washed 3 times with sterile water. Biofilms 
were then stained with 150 µl of 0.1% crystal violet for 15 minutes at 200 rpm. Excess dye was 
removed and the biofilms washed 3 times with sterile water. The plates were allowed to dry then 
the crystal violet was solubilized in 150 µl of 95% ethanol. Crystal violet absorbance 
measurements at 595 nm were taken using an MD SPECTRAmax plate reader (Molecular Devices 
Corporation, USA). This experiment was performed in triplicate and the sample sizes were 
between 12 and 48.   
41 
3.2.6 Candida albicans biofilm formation assay  
Candida albicans biofilms were cultivated according to Pierce et al., 2015 with 
modifications (136). Thawed C. albicans cultures were streaked on YPD agar and incubated 
overnight at 37 ⁰C. The following day, 25 ml YPD broth was inoculated with a loopful of colonies 
and incubated at 30 ⁰C for 14-16 h. Samples of overnight culture were stained with 0.1% v v-1 
methylene blue and cell densities were quantified using a hemocytometer. After quantification, C. 
albicans cells were centrifuged and washed twice with PBS and adjusted to a final concentration 
of 1x10⁷ cells in filter sterilized RMPI-MOPS. Diluted cultures were combined with gesho extract 
to a final concentration of 7 mg ml-1.  Treatments were then serially diluted to final concentrations 
of 5, 3, 1, 0.5 and 0.25 mg ml-1. No vehicles were added to solubilize the treatments. Negative 
controls consisted of cells diluted in RMPI-MOPS without plant extract. 100 µl of treated and 
untreated samples were added to each well of a microtiter plate and incubated at 37 ⁰C, 200 rpm 
for 24 h. The next day, planktonic cells and spent media were removed from each well and the 96 
well plates were washed 3 times with sterile water. Biofilms were then stained with 150 µl of 0.1% 
crystal violet for 15 min at 200 rpm (137, 138). Excess dye was removed, and the biofilms washed 
3 times with sterile water. The plates were allowed to dry then the crystal violet was solubilized in 
150 µl of 95% ethanol. Crystal violet absorbance measurements at 595 nm were taken using an 
MD SPECTRAmax plate reader (Molecular Devices Corporation, USA) (97). This experiment 
was performed in triplicate and the sample sizes ranged between 16 and 39.  
3.2.7 Streptococcus mutans and Candida albicans dual-species biofilm formation 
assay 
In vitro growth of polymicrobial biofilms was conducted according to de Oliveira et al., 
2017 with modifications (139). S. mutans and C. albicans inocula were prepared as stated above. 
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BHI-sucrose S. mutans and RPMI-MOPS C. albicans inocula were combined at equal volumes 
and mixed thoroughly. Co-cultures were combined with gesho extract to a final concentration of 
3 mg ml-1 and 100 µl of treated and untreated samples were added to each well of a microtiter 
plate. Plates were then incubated at 37 ⁰C, 200 rpm for 24 h. No vehicles were added to solubilize 
the treatments. Negative controls consisted of diluted cells without plant extract. The following 
day, plates were washed, stained and measured as stated above. Experiments were performed in 
triplicate. 
3.2.8 Planktonic growth assay  
Streptococcus mutans and Candida albicans overnight cultures were prepared as stated 
above. Secondary overnight cultures of Streptococcus mutans, Candida albicans and combined 
Streptococcus mutans and Candida albicans were prepared in 20 ml of BHI, YPD and 1:1 BHI-
YPD, respectively. Secondary overnight broth cultures were then diluted to an initial OD600 of 0.01 
(approximately 2.4 x106 viable S. mutans cells and 1.5 x104 viable C. albicans cells per milliliter 
of culture) in 15 ml of fresh 1:1 BHI-YPD broth. GSE was added to a final concentration of 3 mg 
ml-1.  Negative controls consisted of cells diluted in broth media without plant extract. Cultures 
were statically incubated at 37 °C for 9 h and samples were taken at every hour for agar plating. 
Time point samples were serially diluted (1:10) in PBS and radially plated on BHI agar plates. 
Agar plates were incubated overnight at 37 °C to allow for colony formation and plate counts were 
used to quantify cell density and growth. Co-culture S. mutans and C. albicans colonies were 
differentiated microscopically based on colony morphology. YPD and BHI were used for growth 
experiments to avoid bacterial flock formation which occurs when sucrose is present in the media. 
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3.2.9 Streptococcus mutans regrowth assay 
Streptococcus mutans overnight cultures were prepared as stated above and secondary 
overnight cultures were prepared in 20 ml of BHI. Secondary overnight broth cultures were then 
diluted to an initial OD600 of 0.01 (approximately 2.4 x10
6 viable S. mutans cells per milliliter of 
culture) in 15 ml of fresh 1:1 BHI-YPD broth. GSE was added to the treatment flasks to a final 
concentration of 3 mg ml-1.  Negative controls consisted of cells diluted in broth media without 
plant extract. Cultures were statically incubated at 37 °C for 24 h. After 24 hours, 500 µl of each 
culture were added to a new flask of 15 ml BHI-YPB broth. Regrowth cultures were statically 
incubated at 37°C for 48 hours and samples were taken at t = 0, 8, 24 and 48 hours for agar plating. 
Time point samples were serially diluted (1:10) in PBS and radially plated on BHI agar plates. 
Agar plates were incubated overnight at 37 °C to allow for colony formation and plate counts were 
used to quantify cell density and growth.  
3.2.10 Biofilm killing assay 
Streptococcus mutans, Candida albicans and dual-species biofilms were formed as 
described above. Biofilms were allowed to form at 37 ºC for 24 h.  After incubation, spent media 
was removed and biofilms were washed twice with 150 µl of PBS. Gesho extracts were suspended 
in fresh, sterile media to a final concentration of 7 mg ml-1. Treatments were then diluted to final 
concentrations of 5, 3, 1, 0.5, 0.25 and 0.12 mg ml-1. No vehicles were added to solubilize the 
treatments. 100 µl of each treatment was added to each well of the microtiter plate and incubated 
at 37 °C for an additional 24 h. Negative controls consisted of 100 µl of fresh media without 
extract. After 24 h, planktonic cells and spent media were removed from each well and the biofilms 
were washed twice with 150 µl of PBS. 100 µl of resazurin (10 µg ml-1) or XTT (0.5 mg ml-1) in 
broth media were added to each biofilm. Plates were statically incubated at 37 ºC for 1 h for S. 
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mutans or 3 h for C. albicans and co-cultures. Resazurin fluorescence intensity was measured at 
λex= 570 nm λem= 590 nm using an Enspire fluorescence plate reader (PerkinElmer, USA) while 
XTT was measured at absorbance of 490 nm using a Victor plate reader (PerkinElmer, USA). Data 
were normalized to the untreated control. Experiments were performed in triplicate and the sample 
sizes ranged between 6-12 for treated samples and 14-24 for the untreated controls. 
3.2.11 Streptococcus mutans polysaccharide production 
Eight biofilms were formed for each treatment. Streptococcus mutans biofilms were 
formed as stated above. After 24 h of incubation, planktonic cells and spent media were removed 
from each well and the remaining biofilms were washed twice with 150 µl of PBS. 150 µl of 0.1% 
Direct Yellow 96 in PBS was then added to four biofilm wells and incubated in the dark, at room 
temperature for 30 min. Direct Yellow 96 binds polysaccharides such as beta glucans and was used 
for polysaccharide quantification. After incubation, unbound Direct Yellow 96 was aspirated and 
the biofilms were washed twice with 150 µl PBS. 100 µl of PBS were then added to each well and 
the fluorescence intensity was measured on a Victor plate reader at λex= 405 nm; λem= 535 nm. 
Biofilm cells were scraped from the surface of the remaining four wells and collected into 400 µl 
of PBS. Biofilm cells were then serially diluted (1:10) in PBS and plated on BHI agar. Agar plates 
were incubated at 37 °C for 48 h and plate counts were used to measure cell density. Polysaccharide 
concentrations were calculated by adjusting the fluorescence intensity to the number of cells. 
Experiments were performed in triplicate.  
3.2.12 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 22.0 software and VasserStats: 
website for statistical computation. Non-parametric (Kuskal-Wallis Test and Median Test) or 
parametric (ANOVA and t-tests) analyses were performed based on the characteristics of the data. 
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Comparisons were conducted between control (untreated) and gesho treated samples. Differences 
with a p-value < 0.05 were considered statistically significant. 
3.3 Results and Discussion 
3.3.1 Gesho ethanol extracts inhibit Streptococcus mutans and Candida albicans 
mono-species biofilm formation 
Previously, our laboratory reported the inhibitory effects of gesho extracts on Gram 
positive mono-species biofilm formation (134). In that work, gesho ethanol extracts were found to 
significantly inhibit Streptococcus mutans biofilm formation at 3, 5 and 7 mg ml-1 of treatment 
(134); however, the effects of extract treatment on polymicrobial biofilms or eukaryotic 
microorganisms were not assessed. The aim of this work was to expand on the anti-biofilm 
activities of gesho ethanol extracts and identify possible mechanisms of action. Gesho leaf and 
stem extracts significantly impacted S. mutans and C. albicans mono-species biofilm formation, 
resulting in up to 77 and 75 percent inhibition, respectively (Table 2). Treatment concentrations of 
3, 5, and 7 mg ml-1 of extract on S. mutans caused up to 97 percent inhibition and are reported in 
Campbell et al., 2019. Both extracts were effective; however, the stem extract (GSE) exhibited 
overall greater percentages of inhibition when compared to the leaf extract (GLE) at the same 
treatment concentrations. The effects of treatment on each species were different; S. mutans 
treatments were concentration-dependent while C. albicans treatment efficacies leveled off at 
approximately 50 percent inhibition relative to the untreated control for all concentrations ≥ 0.5 
mg ml-1 GSE. The anti-biofilm activities of gesho were similar to those reported for other plant 
extracts (127, 129, 139, 140). Due to the superior inhibitory activity of GSE on mono-species 
biofilms, we evaluated the impact of GSE on S. mutans and C. albicans dual-species biofilm 
formation. 
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3.3.2 Gesho stem ethanol extract prevents Candida albicans and Streptococcus 
mutans dual-species biofilm formation 
In co-culture, GSE not only impaired the ability of each species to form biofilms 
independently but also disrupted their synergistic relationship. C. albicans and S. mutans co-
cultures were treated with 3 mg ml-1 GSE due to its efficacy in treating S. mutans and C. albicans 
mono-species biofilms (Table 2).  In the untreated controls, co-culture biofilm formation was 
enhanced more than 5-fold compared to mono-species biofilms, indicating a synergistic interaction 
(Figure 11). In contrast, GSE inhibited dual-species biofilm formation by 97 percent relative to the 
untreated control. These observations were similar to the inhibitory effects on C. albicans and S. 
mutans polymicrobial biofilms reported for Rosmarinus officinalis extract, Camellia sinensis-
derived polyphenol 60, eugenol and thiazolidnedione-8 (139, 141).  
3.3.3 Gesho stem ethanol extract inhibits Streptococcus mutans planktonic growth    
We assessed whether GSE was inhibitory to planktonic growth and whether synergistic 
interactions were evident. In the absence of GSE, S. mutans and C. albicans in co-culture exhibited 
similar growth rates as when each species was grown alone, indicating that, in planktonic culture, 
no synergism occurred (Figure 12). This behavior is in contrast to what was observed in co-culture 
biofilms. 3 mg ml-1 GSE did not impact the growth of C. albicans in mono- or co-culture. On the 
other hand, GSE prevented the growth of S. mutans, acting in a bacteriostatic manner (Figure 12). 
After 24 hours of exposure to 3 mg ml-1 GSE, S. mutans was inoculated into fresh media with no 
GSE; there was an increase in cell density from 1.8x103 to 2.7 x108 CFU ml-1 after 48 hours (Table 
3).  
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3.3.4 Gesho extracts impact the metabolic activity of biofilm dwelling cells 
Biofilm dwelling cells are frequently resistant to chemical treatments due to the presence 
of a dense extracellular matrix, metabolically attenuated cells and persister cells (7). GSE was 
effective in reducing the metabolic activity of S. mutans and C. albicans in established mono-
species biofilms (Table 4). After 24 h of growth 3 mg ml-1 GSE was added to wells containing 
growing biofilms; after an additional 24 h, the metabolic activity for S. mutans and C. albicans 
mono-species biofilms were 23 and 55 percent relative to untreated controls, respectively (Table 
4). In contrast, adding 3 mg ml-1 GSE to established S. mutans-C. albicans dual species biofilms 
increased metabolic activity more than 50 percent with respect to untreated controls. These data 
illustrate the strength of the synergism between the two species and demonstrate the challenge of 
treating polymicrobial biofilms.  
3.3.5 Gesho extracts decrease polysaccharide production by Streptococcus mutans 
biofilm cells 
Beta glucans are the major polysaccharide present in S. mutans biofilms and greatly 
impacts mono- and dual-species biofilm formation (142). Plant extracts and pure compounds have 
been found to inhibit S. mutans biofilm formation through preventing beta glucan production (128, 
140); we hypothesized that gesho extracts could act in a similar manner. A fluorescent dye that 
binds to polysaccharides, Direct Yellow 96, was used to assess the effects of the stem ethanol 
extract on polysaccharide concentrations in the S. mutans biofilm matrix. A decrease in 
fluorescence indicated that extract treatments decreased polysaccharide production in a dose 
dependent manner with almost no glucans present at higher treatment concentrations (Figure 13). 
As beta glucans make up a significant proportion of biofilm matrix polysaccharides, these data 
indicated a potential mechanism by which GSE inhibited mono- and dual-species biofilm 
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formation. Beta glucans are synthesized by glucosyltransferase (Gtf) proteins through enzymatic 
conversion of sucrose (142). We hypothesize that compounds in the stem extract inhibit S. mutans 
Gtf glucan production, reducing S. mutans biofilm formation. It follows that the decrease in S. 
mutans and C. albicans dual species biofilm formation is also impacted by the reduction in glucans, 
as both organisms have been shown to use Gtf enzymes and glucans for attachment and biofilm 
enhancement (125, 126, 143). Overall, GSE promises to be a source of compounds that can inhibit 
S. mutans-C. albicans dual species biofilm formation.       
Gesho is used in traditional medicine and our findings support its use as an antimicrobial 
and anti-biofilm agent. The data presented regarding GSE’s efficacy against S. mutans and C. 
albicans biofilm formation and planktonic growth aligns with an earlier report regarding gesho’s 
ability to control S. aureus and B. subtilis biofilms (134).  Campbell et al., 2019 identified two 
pure compounds from gesho leaf extract and together with this work, demonstrate that both the R. 
prinoides leaf and stem are sources of bioactive compounds useful for controlling microbial 
pathogens. The effect of GSE on C. albicans was notable in that it did not negatively impact growth 
but still inhibited biofilm formation.  This combination of traits is indicative of an “anti-
pathogenic” treatment. Anti-pathogenic therapeutics target microbial virulence but are non-
biocidal; this reduces selective pressure resulting in antimicrobial resistance (65). To our 
knowledge, this work was the first to investigate the antimicrobial effects of Rhamnus prinoides 
extracts on Candida albicans or polymicrobial biofilms. To better understand the potential 
applications of gesho and gesho-derived compounds, further work into the chemical compositions 
and mechanisms should be conducted including investigations into Gtf binding and expression. 
Based on the data collected to date, gesho shows promise as a natural product that can be 
incorporated into oral hygiene products. 
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3.4 Figures and Tables 
 
Table 2. Inhibition of biofilm formation by gesho ethanol extracts 
 
 Concentration 
(mg ml-1) 
Percent inhibition2 
Extract S. mutans C. albicans 
GLE1 0.0 
0.2 
0.5 
1.0 
3.0 
5.0 
7.0 
0 ± 1 
13 ± 1* 
14 ± 2* 
26 ± 7* 
Campbell et al., 2019 
Campbell et al., 2019 
Campbell et al., 2019 
0 ± 3* 
52 ± 10* 
47 ± 10* 
51 ± 10* 
59 ± 9** 
46 ± 14* 
51 ± 10* 
GSE1 0.0 
0.2 
0.5 
1.0 
3.0 
5.0 
7.0 
0 ± 3 
33 ± 6* 
67 ± 5* 
77 ± 3* 
Campbell et al., 2019 
Campbell et al., 2019 
Campbell et al., 2019 
0 ± 3 
32 ± 9* 
65 ± 3* 
73 ± 3* 
68 ± 6* 
75 ± 2* 
70 ± 2* 
 
 
 
 
 
** Figure originated from the thesis of Raghda Ayman Ahmed Fathi, 2018, "Rhamnus prinoides 
(gesho) extract inhibits Streptococcus mutans and Candida albicans polymicrobial biofilm 
formation." Georgia State University. https://scholarworks.gsu.edu/biology_theses/82 
 
 
1Leaf ethanol (GLE) and stem ethanol (GSE) treatments 
2Percent inhibition are the mean of treated samples relative 
to the untreated control within the same species ± SEM 
* indicates a significant difference (p< 0.05) between the 
treated sample and the untreated control 
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Figure 11. GSE inhibits Streptococcus mutans and Candida albicans dual species biofilm 
formation. 
C. albicans (CA), S. mutans (SM) and dual species (SM+CA) biofilm formation were assessed 
after treatment with GSE (grey bars). Untreated biofilms acted as negative controls (white bars). 
Inset depicts biofilm formation of GSE treated samples only. All assays were performed in 
triplicate (n= 30). Error bars are standard error of the mean. Letters a, b and c indicate a 
significant difference (p< 0.05) between a treated sample and its corresponding untreated control. 
Asterisks indicate a significant difference among untreated or treated samples. 
 
** Figure originated from the thesis of Raghda Ayman Ahmed Fathi, 2018, "Rhamnus prinoides 
(gesho) extract inhibits Streptococcus mutans and Candida albicans polymicrobial biofilm 
formation." Georgia State University. https://scholarworks.gsu.edu/biology_theses/82 
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Figure 12. GSE arrests Streptococcus mutans growth. 
The planktonic growth of S. mutans (SM) and C. albicans (CA) mono- and co-cultures were 
assessed in the absence or presence of 3 mg/mL GSE. Solid lines represent untreated cultures 
while treated cultures are represented by dashed lines. 
 
 
 
 
 
 
 
 
 
 
B 
A 
Figure 2. GSE arrests Streptococcus mutans growth. The planktonic growth 
of S. mutans (SM) and C. albicans (CA) mono- and co-cultures were assessed in 
the absence or presence of 3 mg/mL GSE. Solid lines represent untreated 
cultures while treated cultures are represented by dashed lines. 
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Table 3. Streptococcus mutans regrowth after GSE removal 
 Cell counts ( x104) 
Time Untreated control 3 mg ml-1 GSE 
0 339 ± 237 0.2 ± 0.2 
8 24523 ± 16140 0.1 ± 0.1 
24 13250 ± 8567 1668 ± 1666 
48 0 ± 0 26500 ± 3500 
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Table 4. Metabolic activity of biofilm dwelling cells after exposure to stem ethanol 
extracts 
 
 
 
 
 
Percent biofilm formation are the mean of extract treated samples relative to the untreated 
control for each species± the standard error of the mean (SEM).  
*indicate a significant difference (p< 0.05) between the treated samples 
 
 
 
 
 
 
 
 
 
 
Concentration 
(mg/mL) 
Streptococcus 
mutans 
Candida 
albicans 
S. mutans and 
C. albicans 
0 
0.2 
0.5 
1 
3 
5 
7 
100 ± 1.9 
66 ± 6* 
51 ± 7* 
37 ± 9* 
23 ± 5* 
31 ± 3* 
23 ± 4* 
100 ± 0.9 
73 ± 3* 
67 ± 2* 
60 ± 3* 
56 ± 2* 
53 ± 2* 
54 ± 1* 
100 ± 0.6 
108 ± 4 
121 ± 7* 
131 ± 4* 
145 ± 5* 
152 ± 2* 
164 ± 6* 
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Figure 13. GSE decreases Streptococcus mutans glucan production. 
Glucan concentration in S. mutans biofilms was assessed in the absence or presence of 3 mg/mL 
GSE. All assays were performed in triplicate. Error bars are standard error of the mean. Asterisk 
(*) indicates a significant difference (p< 0.05) between the untreated and treated samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
  
 
 
 
 
* * 
Figure 3. GSE decreases Streptococcus mutans glucan production. Glucan 
concentration in S. mutans biofilms was assessed in the absence or presence of 
3 mg/mL GSE. All assays were performed in triplicate. Error bars are standard 
error of the mean. Asterisk (*) indicates a significant difference (p< 0.05) 
between the untreated and treated samples. 
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4 4-ETHOXYBENZOIC ACID INHIBITS STAPHYLOCOCCUS AUREUS BIOFILM 
FORMATION AND POTENTIATES BIOFILM SENSITIVITY TO VANCOMYCIN  
4.1 Introduction 
Infections involving bacterial biofilms are notoriously difficult to treat due to their enhanced 
antibiotic resistance (7). Eradicating biofilms is further complicated by a global increase in 
antibiotic resistance among pathogens resulting from antibiotic misuse and overuse (144). A 
logical response to these interrelated problems is non-bactericidal therapeutic agents that prevent 
biofilm formation and also increase antibiotic susceptibility; such compounds would extend the 
longevity of currently used antibiotics and reduce selective pressure favoring resistance. These 
compounds are referred to as anti-pathogenic agents. An example of such a compound is 
hamamelitannin, which prevents Staphylococcus aureus biofilm formation and sensitizes it to 
vancomycin (71). Nonetheless, more anti-biofilm compounds with anti-pathogenic features are 
needed to diversify the existing arsenal (65).   
In recent work, we identified two compounds from Rhamnus prinoides, an east African shrub 
used in traditional medicine, that prevented biofilm formation by Gram positive bacteria (134). 
Notably, ethoxy-4-hydroxybenzoic acid (EEB) reduced biofilm formation by Staphylococcus 
aureus by 60 percent with minimal inhibition of growth, a feature associated with anti-pathogenic 
compounds (134). Using EEB as a starting point, in this work, we screened the activity of 
compounds with related structures to identify more potent anti-biofilm compounds with anti-
pathogenic characteristics. This work describes the effects of the compound 4-ethoxybenzoic acid 
(4EB) on S. aureus biofilm formation, antibiotic sensitivity and metabolite production.  
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4.2 Materials and Methods 
4.2.1 Bacterial culture conditions and reagents 
Staphylococcus aureus ATCC 6538 was grown in Luria-Bertani (LB) broth (Becton 
Dickinson and Company, USA). Compounds assessed in this study include: 2- hydroxybenzoic 
acid (salicyclic acid), 3-hydroxybenzoic acid, 4-hydroxybenzoic acid (paraben), 4-
hydroxybenzoic acid methyl ester (methyl paraben), 2,3-dihydroxybenzoic acid (pyrocatechuic 
acid), 2,5-dihydroxybenzoic acid (gentisic acid), 3,4-dihydroxybenzoic acid (protocatechuic acid), 
gallic acid, methyl gallate, ethyl gallate, propyl gallate, 4-ethoxybenzoic acid and ethyl 4-
ethoxybenzoic acid. The following reagents were purchased from Fisher Scientific (USA): crystal 
violet, dimethyl sulfoxide, 4-ethoxybenzoic acid, ethyl gallate, gallic acid, hexadecane, 3-
hydroxybenzoic acid, methyl gallate, potassium chloride, dibasic potassium phosphate, monobasic 
potassium phosphate and sodium chloride. Reagents purchased from Sigma, Aldrich or Sigma-
Aldrich (USA) include: hexadecane, gentisic acid, p-hydroxybenzoic acid, methyl paraben, 
protocatchuic acid, pyrocatechuic acid, resazurin, salicylic acid, fluorescein 5(6)-isothiocyanate 
(FITC) and vancomycin. Bacto agar, yeast extract and tryptone were purchased from BD 
Biosciences (USA). Ethyl 4-ethoxybenzoic acid, 95% ethanol, propyl gallate, and rabbit’s blood 
were purchased from Combi-Blocks (USA), Decon Labs (USA), Nutritional Biochemical 
Corporation (USA) and Hemostat Laboratories (USA). Florescent dyes SYBR Safe, propidium 
iodide, and Direct Yellow 96 were purchased from Invitrogen, Acros Organics and AK Scientific, 
respectively.  
4.2.2 Biofilm formation assay 
Biofilm formation was assessed using a polystyrene 96 well microtiter plate crystal violet 
assay (97). Overnight broth cultures were diluted to an initial OD600 of 0.01 in fresh LB broth and 
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combined with a target compound to obtain a final concentration of 7 mg/ml. Diluted cells (OD600 
= 0.01) were then used to serially dilute the compound to final treatment concentrations of 5, 3, 1, 
0.5 and 0.25 mg/ml. No vehicles were added to solubilize the treatments. Untreated cells served 
as negative controls. One hundred microliters of treated and untreated samples were added to each 
well of a microtiter plate and incubated at 37 °C, 200 rpm for 24 h (98, 99). After 24 h, planktonic 
cells and spent growth media were removed from each well and the plate was washed 3 times in 
sterile water. Biofilms were then dried at room temperature or 37 °C and stained with 150 µl of 
0.1% crystal violet for 15 min at 200 rpm. Excess dye was removed via washing in sterile water 
and the plate was allowed to air dry. Crystal violet was solubilized in 150 µl of 95% ethanol and 
absorbance measurements at 595 nm were taken using an MD SPECTRAmax plate reader 
(Molecular Devices Corporation, USA).  
4.2.3 Resting cell viability assay  
To quantify the viability of stationary phase planktonic cells, a growth agar-based assay 
was conducted. Spent media containing stationary phase planktonic cells were collected from 
microtiter plates after the conclusion of each biofilm formation assay. The collected cells were 
serially diluted (1:10) in PBS and dilutions were radially plated in 10 µl volumes on agar growth 
medium. Agar plates were incubated at 37 °C overnight to allow for colony formation and plate 
counts were used to assess viability. Colony forming units per milliliter of culture (CFU/ml) was 
calculated by dividing the colony counts (C) by the volume added (V) multiplied by the dilution 
factor (D): CFU/ml = C / (V x D). 
4.2.4 Vancomycin MIC assay 
Overnight broth cultures were diluted to an initial OD600 of 0.01 in fresh LB broth and 
combined with vancomycin to a concentration of 1600 µg/ml. Diluted cells (OD600 = 0.01) were 
58 
then used to serially dilute the vancomycin to final treatment concentrations of 800, 400, 200, 100, 
50, 25, 12.5, 6.3, 3.1, 1.6 and 0.8 µg/ml. Untreated cells served as negative controls. One hundred 
microliters of treated and untreated samples were added to each well of a microtiter plate and 
incubated at 37 °C, 200 rpm for 24 h. Sample turbidities were then measured at an optical density 
600 nm using an MD SPECTRAmax plate reader (Figure 16). The lowest concentration of 
vancomycin to inhibit planktonic growth (1.6 µg/ml) was used for subsequent growth curve assays 
(Figure 16). 
4.2.5 Staphylococcus aureus growth curve 
Overnight broth cultures were diluted to an initial OD600 of 0.01 in fresh LB broth and 
combined with 4-ethoxybenzoic acid (0.2 or 0.4 mg/ml), methyl gallate (0.2 or 0.4 mg/ml) or 
methyl paraben (0.8 mg/ml). Two milliliters of each treatment was added to 19 culture tubes and 
the samples were incubated for 24 h at 37 °C with shaking at 200 rpm. One culture tube from each 
sample was removed every hour and optical density measurements at 600 nm were taken. Time 
points were taken every hour for 9 hours. Final measurements were taken at 24 h the following 
day. Untreated samples and samples containing 1.6 µg/ml vancomycin served as negative and 
positive controls, respectively. Specific growth rates were calculated based on measurements made 
during the first four hours.  
4.2.6 Resazurin standard curve 
Overnight broth cultures of Staphylococcus aureus were diluted to an OD600 of 0.01 in 
fresh LB broth and incubated at 37°C, 200 rpm for 3 hr. After incubation, the optical density of 
the culture was measured and the culture was then diluted to an OD600 of 1.0; this culture was then 
diluted to optical densities (600 nm) of 0.5, 0.25, 0.12, 0.06, 0.03, 0.01, 0.008, 0.004 and 0.002. 
Cellular respiration was measured by adding 50 µl of each dilution to a 96 well plate followed by 
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the addition of 50 µl of 20 µg/ml resazurin solution, prepared in LB broth. Resazurin is a blue, 
non-fluorescent oxidation-reduction indicator that is converted to the pink fluorescent intermediate 
resorufin upon reduction. The 96 well plate was statically incubated for 3 hr at 37 °C. During 
incubation, fluorescence intensity was measured at λex= 570 nm λem= 590 nm every 6 minutes 
using an Enspire fluorescence plate reader (PerkinElmer, USA); these measurements were used to 
identify the time at which maximum fluorescence was achieved. Cell concentrations (CFU/ml) 
that correspond with resazurin samples were quantified using serial dilutions followed by plate 
counts. Samples were serially diluted (1:10) in PBS and dilutions were radially plated in 10 µl 
volumes on growth medium. Agar plates were incubated at 37 °C for 24 hours to allow for colony 
formation. 
4.2.7 Vancomycin MBC assay 
Staphylococcus aureus biofilms were formed as described above. Staphylococcus aureus 
biofilms were grown in LB broth. Overnight broth cultures were diluted to an initial OD600 of 
0.01 in fresh media and 100 µl of culture was added to each well of a 96 well polystyrene 
microtiter plate; biofilms were allowed to form at 37 ºC for 24 hrs.  After incubation, spent 
media were removed and biofilms were washed twice with 150 µl of PBS. Vancomycin was 
suspended in LB broth to a final concentration of 1600 µg/ml. Treatments were then serially 
diluted to obtain concentrations of 800, 400, 200, 100, 50, 25, 12.5, 6.3, 3.1, 1.6 and 0.8 µg/ml. 
Negative controls consisted of 100 µl of fresh LB without vancomycin. One hundred microliters 
of each treatment were added to each microtiter plate biofilm and incubated at 37 °C for 24 h. 
After 24 h, planktonic cells and spent growth media were removed from each well and the 
biofilms were washed twice with 150 µl of PBS. One hundred microliters of 10 µg/ml resazurin 
in LB were added to each biofilm and the plate was statically incubated at 37 ºC for 3 hrs. 
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During incubation, fluorescence intensity was measured at λex= 570 nm λem= 590 nm every 6 
minutes using an Enspire fluorescence plate reader (PerkinElmer, USA). Data were normalized 
to the emission reading at t = 0 and the rates of resazurin conversion to resorufin were calculated 
to identify the time at which maximum fluorescence was achieved. The number of viable biofilm 
cells were estimated using a resazurin standard curve that correlated bacterial cell density with 
the time required to reach maximum fluorescence intensity (Figure 18 and Table 8). 
4.2.8 Staphylococcus aureus biofilm killing assay  
Staphylococcus aureus biofilms were formed as described above. Staphylococcus aureus 
biofilms were grown in LB broth. Overnight broth cultures were diluted to an initial OD600 of 0.01 
in fresh media and 100 µl of culture was added to each well of a 96 well polystyrene microtiter 
plate; biofilms were allowed to form at 37 ºC for 24 hrs.  After incubation, spent media were 
removed and biofilms were washed twice with 150 µl of PBS. Methyl gallate or 4-ethoxybenzoic 
acid were suspended in LB broth to a final concentration of 7 mg/ml. Treatments were then serially 
diluted to obtain concentrations of 3.5, 1.7, 0.8, 0.4, 0.2 and 0.1 mg/ml. Vancomycin treatments 
were diluted to a final concentration of 3.1 µg/ml. No vehicles were added to solubilize the 
treatments. Negative controls consisted of 100 µl of fresh LB without compound or antibiotic. One 
hundred microliters of each treatment were added to each well of a microtiter plate and incubated 
at 37 °C, 200 rpm for 24 h. After 24 h, planktonic cells and spent growth media were removed 
from each well and the biofilms were washed twice with 150 µl of PBS. One hundred microliters 
of 10 µg/ml resazurin in LB was added to each biofilm and the plate was statically incubated at 37 
ºC for 3 hrs. During incubation, fluorescence intensity was measured at λex= 570 nm λem= 590 nm 
every 6 minutes using an Enspire fluorescence plate reader (PerkinElmer, USA). Data were 
normalized to the emission reading at t = 0 and the rates of resazurin conversion to resorufin were 
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calculated to identify the time at which maximum fluorescence occurred. The number of viable 
biofilm cells were estimated by using a standard curve that correlated the rate of resazurin 
reduction (time to maximum fluorescence) with cell number per ml (Figure 18).  
4.2.9 Staphylococcus aureus hemolysis assay 
Hemolysis activity was assessed according to Lee, et al, 2014 with a few modifications 
(61). Overnight Staphylococcus aureus broth cultures were diluted to an initial OD600 of 0.01 in 
fresh LB containing 4-ethoxybenzoic acid at 0.2 or 0.4 mg/ml. Cultures were then incubated for 
24 h at 37 °C with shaking at 200 rpm. One milliliter of each sample was transferred to 1.5 ml 
microfuge tubes and centrifuged at 10,000 rcf for 2 minutes. One hundred microliters of 
supernatant was added to 900 µl of 4% rabbit’s blood (previously washed twice with 1X PBS via 
centrifugation at 800 rcf for 2 min). Hemolysis samples were incubated for 1 h at 37 °C, shaking 
at 200 rpm. PBS and 10% SDS treated samples served as negative and positive controls, 
respectively. Samples were then centrifuged at 2,000 x g for 5 min to pellet any intact blood cells. 
One hundred microliters of each supernatant were added to a 96 well microtiter plate and 
absorbance measurements at 450 nm were taken using an MD SPECTRAmax plate reader 
(Molecular Devices Corporation, USA). 
4.2.10 Hydrophobicity test (Microbial Adherence to Hydrocarbon Test) 
Hydrophobicity analysis was conducted according to Ciccio, et al., 2015 with a few 
modifications (145). Three milliliters of Staphylococcus aureus cultures were grown in the 
presence of 4-ethoxybenzoic acid (0.2 or 0.4 mg/ml) for 24 h at 37 °C with shaking at 200 rpm. 
Cultures were diluted to an OD600 of 0.6 and washed with 1 ml PBS. Five milliliters of the 
inoculum were produced, 1 ml was removed for plating on growth agar and 1 ml of hexadecane 
was applied to the air-liquid interface or the remaining 4 ml. Hexadecane samples were vortexed 
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for 1 min and the phases allowed to separate for 15 minutes at room temperature. One milliliter of 
the aqueous layer was removed and plated on growth agar. Agar plates were incubated at 37 °C 
overnight and plate counts were conducted the following day. Results were interpreted as the 
percent of cells present in the aqueous layer prior to (A0) and after (A1) the addition of hexadecane 
[(A0-A1)/A0]*100.  
4.2.11 Membrane integrity assay 
Membrane integrity assays were conducted according to Brackman et al, 2016 with a few 
modifications (71). Overnight broth cultures of S. aureus were washed and diluted to an initial 
optical density (600 nm) of 1.0 in PBS. A 7 mg/ml stock solution of 4-ethoxybenzoic acid was 
prepared in diluted cells (OD600 = 1.0); the stock was then diluted to final treatment concentrations 
of 0.4 and 0.2 mg/ml in diluted cells (OD600 = 1.0). Two milliliters of each treatment were added 
to sterile polystyrene culture tubes and incubate at 37 °C, 200 rpm for 24 hrs. Untreated cells and 
heat-treated cells were used as the negative and positive control, respectively. Heat-treated cells 
were prepared by incubating 500 µl of diluted cells (OD600 = 1.0) in a 98 °C water path for 10 
minutes. Fifty microliters of each sample was added to a 96 well plate followed by the addition of 
50 µl of 10 µg/ml propidium iodide. 96 well plates were incubated in the dark for 15 minutes then 
read on an Enspire plate reader at λex= 535 nm; λem= 617 nm. 
4.2.12 Crystal violet standard curve 
Staphylococcus aureus biofilms were formed as stated above. Overnight broth cultures 
were diluted to an initial OD600 of 0.01 and treated with 4EB at final concentrations of 0.1, 0.2, 
0.4, 0.8, 1.6 and 3.5 mg/ml. One hundred microliters of treated cells were added to each well of a 
microtiter plate and incubated at 37 °C, 200 rpm for 24 h. Five biofilms were tested for each 
treatment concentration. After 24 h of incubation, planktonic cells and spent media were removed 
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from each well and the remaining biofilms were washed twice with 150 µl of PBS. One hundred 
microliters of PBS was added to two biofilm wells for each treatment and a sterile pipet tip was 
used to detach the biofilms from the wells.  Detached cells were then serially diluted (1:10) in PBS 
and dilutions were radially plated in 10 µl volumes on growth medium. Agar plates were incubated 
at 37 °C for 24 hours to allow for colony formation prior to conducting plate counts. Biofilms in 
the remaining 3 wells were stained with crystal violet as detailed above. A standard curve that 
correlated biofilm cell density (crystal violet absorbance) to S. aureus cell number (CFU/ml) was 
prepared and was subsequently used to normalize the measurements of proteins, polysaccharides 
and eDNA present in the biofilm EPS (Figure 20). 
4.2.13 Staphylococcus aureus extracellular polysaccharide production 
Staphylococcus aureus biofilms were formed as stated above. Overnight broth cultures 
were diluted to an initial OD600 of 0.01 and treated with 4EB at final concentrations of 0.2, 0.4 and 
0.8 mg/ml. One hundred microliters of treated cells were added to each well of a microtiter plate 
and incubated at 37 °C for 24 h. Six biofilms were tested for each treatment concentration. After 
24 h of incubation, planktonic cells and spent media were removed from each well and the 
remaining biofilms were washed twice with 150 µl of PBS. One hundred-fifty microliters of 0.1% 
Direct Yellow 96, a fluorescent polysaccharide-binding dye, in PBS were then added to 3 biofilm 
wells and incubated in the dark, at room temperature for 30 min. After incubation, unbound Direct 
Yellow 96 was aspirated and the biofilms were washed twice with 150 µl PBS. One hundred 
microliters of PBS was then added to each well and the fluorescence intensity was measured on a 
Victor V3 plate reader at λex= 405 nm; λem= 535 nm (PerkinElmer, USA). Biofilms in the remaining 
3 wells were stained with crystal violet as detailed above and the biofilm cell density was 
determined. For each sample, relative polysaccharide production was calculated by dividing the 
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measured fluorescence intensity by the corresponding number of biofilm cells. All experiments 
were performed in triplicate.  
4.2.14  Staphylococcus aureus extracellular DNA production 
SYBR Safe (Invitrogen, USA) is a fluorescent nucleic acid stain and was used to quantify 
biofilm extracellular DNA (eDNA). Twelve biofilms were formed for each treatment. 
Staphylococcus aureus biofilms were formed as described above with the addition of SYBR Safe 
to the growth medium (final concentration = 1X). After 24 h of incubation, planktonic cells and 
spent media were removed from each well and the remaining biofilms were washed twice with 
150 µl of PBS. One hundred-fifty microliters of PBS was then added to each well and the 
fluorescence intensity from the biofilm-associated cells was measured on a Victor plate reader at 
λex= 490 nm; λem= 535 nm. Biofilms in the remaining 3 wells were stained with crystal violet as 
detailed above and biofilm cell density was calculated using a standard curve. For each sample, 
relative eDNA production was calculated by dividing the measured fluorescence intensity by the 
corresponding number of biofilm cells. Seven replicates of each condition were performed. 
4.2.15 Staphylococcus aureus extracellular protein production 
Protein quantification assays were conducted according to Stiefel et al, 2016 with a few 
modifications (146). Staphylococcus aureus biofilms were formed as described above. Nine 
replicate biofilms were formed for each treatment. Overnight broth cultures were diluted to an 
initial OD600 of 0.01 and treated with 4EB at final concentrations of 0.2, 0.4 and 0.8 mg/ml. One 
hundred microliters of sample were added to wells of a microtiter plate and incubated at 37 °C for 
24 h. After 24 h of incubation, planktonic cells and spent media were removed from each well and 
the remaining biofilms were washed twice with 150 µl of PBS. One hundred-fifty microliters of 
20 µg/ml fluorescein 5(6)-isothiocyanate (FITC) in water was then added to 5 biofilm wells and 
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incubated in the dark, at room temperature for 30 min. FITC binds proteins and was used to 
quantify proteins in the biofilm matrix. After incubation, unbound FITC solution was aspirated 
and the biofilms were washed twice with 150 µl of a 0.9 percent sodium chloride solution. One 
hundred microliters of water were then added to each well and the fluorescence intensity was 
measured on a Victor plate reader at λex= 485 nm; λem= 535 nm. Biofilms in the remaining 4 wells 
were stained with crystal violet as detailed above and biofilm cell density was estimated using a 
standard curve. For each sample, relative protein production was calculated by dividing the 
measured fluorescence intensity by the corresponding number of biofilm cells. Four replicates of 
each condition were performed.  
4.2.16  Statistical analysis  
Statistical analysis was performed using IBM SPSS Statistics 22.0 software. Non-
parametric (Tukey’s test and Independent samples median test) or parametric (t-test) analyses of 
variance were conducted based on the characteristics of the data. One-Way ANOVA and t-test 
analyses were conducted using VasserStats: Website for Statistical Computation at vasserstats.net. 
Comparisons were conducted between the compound-treated samples and the untreated control. 
Differences with a p-value < 0.05 were considered significant and are designated with an asterisk 
(*). 
4.3 Results 
4.3.1 4-ethoxybenzoic acid, methyl gallate and methyl paraben exhibit anti-
pathogenic anti-biofilm activity  
In previous work, ethyl 4-ethoxybenzoic acid (EEB) inhibited Staphylococcus aureus 
biofilm formation with minimal impact on planktonic growth (134). In an effort to identify 
compounds with greater anti-pathogenic anti-biofilm activity, structurally related compounds to 
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EEB were screened using two parameters (Figure 14). First, we measured the “BP50”, the 
concentration of compound required to inhibit biofilm formation by 50 percent relative to an 
untreated control biofilm. Second, we measured the “LC50”, the concentration of compound 
required to reduce the growth of planktonic cells by 50 percent relative to an untreated control 
sample. The two parameters were graphed on an x-y plot such that the anti-biofilm character 
(BP50) of each compound was presented on the x-axis and the planktonic growth toxicity (LC50) 
was presented on the y-axis (Figure 15). Examination of the graph indicated that the compounds 
clustered in three general categories: low potency (BP50 ≥ 7.5 mM; LC50≥ 15 mM), biocidal 
(LC50 ≤ 15 mM) or anti-pathogenic (BP50 ≤ 7.5; LC50 ≥ 15) based on their BP50 and LC50 
values (Figure 15A, Table 5-6). Molarity was used in this analysis to allow for direct comparisons 
of compound activity; BP50 and LC50 concentrations (molarity and w/v) for each compound are 
provided in Table 6. 
3-hydroxybenzoic acid, paraben, pyrocatechuic acid, gentisic acid, protocatechuic acid, 
ethyl gallate and propyl gallate all possessed LC50 values less than 15 mM and thus were all 
categorized as biocidal regardless of their BP50 (Figure 15A). Low potency compounds included 
gallic acid, salicylic acid and EEB. BP50 and LC50 values for EEB were 104 mM and 818 mM 
respectively (note that EEB could not be seen on the graph with the other compounds). 4-
ethoxybenzoic acid (4EB), methyl gallate and methyl paraben were categorized as anti-pathogenic 
(Figure 15A). The range of possible anti-pathogenic concentrations of 4EB and methyl gallate 
were between 0.1 and 0.8 mg/ml (0.5 mM and 5 mM); for methyl paraben, these concentrations 
were between 0.4 and 1.7 mg/ml (2 mM and 11 mM) (Figure 15B-D). Treatment concentrations 
that inhibited at least 40 percent biofilm formation without inhibiting growth were selected for 
subsequent investigations (Figure 15B-D).   
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4.3.2 4-ethoxybenzoic acid, methyl gallate and methyl paraben attenuate the growth 
of Staphylococcus aureus 
The existence of concentrations of 4EB, methyl gallate and methyl paraben with no 
negative impact on planktonic growth after 24 hours of treatment (Figure 15B-D) led us to 
investigate the impacts of these compounds on the S. aureus log phase growth rate (Table 7 and 
Figure 17). Staphylococcus aureus cells were exposed to 0.2 and 0.4 mg/ml 4EB, 0.2 and 0.4 
mg/ml methyl gallate or 0.8 mg/ml methyl paraben; these concentrations were found to exhibit 
anti-pathogenic inhibition of biofilm formation (Figure 15B-D). At the tested concentrations, 
growth was attenuated by no more than 50 percent relative to untreated cells (Table 7). Treatments 
with 0.2 mg/ml 4EB showed the least effect on growth, which was attenuated by 12 percent, 
followed by 0.8 mg/ml methyl paraben and 0.2 mg/ml methyl gallate, which decreased the growth 
rate by 25 and 30 percent, respectively. Higher concentrations of 4EB and methyl gallate enhanced 
the negative impacts on growth to approximately 46 percent attenuation for both compounds. Due 
to the high concentrations of methyl paraben required to observe an anti-pathogenic phenotype, 
further work was not continued with this compound.  
4.3.3 4-ethoxybenzoic acid and methyl gallate enhance the anti-biofilm activity of 
vancomycin 
Anti-pathogenic, anti-biofilm compounds like hamamelitannin have been found to 
potentiate the activity of vancomycin against biofilm-dwelling cells (71, 147). To determine 
whether 4EB or methyl gallate also had this activity, resazurin viability assays were used to 
quantify the number of live cells in an established S. aureus biofilm after 24 hours of treatment 
with 4EB or methyl gallate alone or in combination with 3.1 μg/ml vancomycin (Table 9). MBEC 
assays were conducted to identify the concentration of vancomycin required to significantly reduce 
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biofilm biomass without eradicating all biofilm cells (Table 8).  Treatment with 3.1 μg/ml 
vancomycin alone killed 85 percent of biofilm cells compared to untreated control biofilms. 
Treatments with only 4EB or methyl gallate resulted in no more than 16 percent reduction in 
viability compared to the untreated control. Combining 3.1 μg/ml vancomycin with 4EB at 
concentrations ≥ 0.1 mg/ml reduced biofilm cell viability by an additional 44 to 85 percent 
compared to the vancomycin-only treated samples, indicating that 4EB potentiated vancomycin 
activity (Table 9). In contrast, methyl gallate in combination with vancomycin did not reduce 
biofilm cell viability compared to vancomycin alone. Given the lack of antibiotic potentiation, 
methyl gallate was excluded from further experiments. 
4.3.4 4-ethoxybenzoic acid alters Staphylococcus aureus hydrophobicity and EPS 
production  
The physiological impacts of 4EB on S. aureus were assessed by measuring its effects on 
membrane integrity, hydrophobicity, hemolysis activity and EPS production. Treatment with 0.4 
mg/ml 4EB significantly decreased the percentage of hydrophobic planktonic S. aureus cells 
relative to the untreated and 0.2 mg/ml treated samples (Figure 19). The percent of hydrophobic 
cells decreased from 78 to 49 percent. In addition to the effect on hydrophobicity, 4EB treatments 
impacted the relative amount of extracellular polysaccharides and proteins in the biofilm matrix 
(Figure 21A-B). Treatments of 0.4 and 0.8 mg/ml 4EB significantly enhanced relative extracellular 
polysaccharide production up to 9-fold while the effect on extracellular protein production was 
more modest with a 1-fold increase. Relative extracellular polysaccharide production steadily 
increased as biofilm formation decreased. The impact of treatment on eDNA was the opposite; the 
amount of eDNA produced decreased as biofilm formation decreased (Figure 21C). No change in 
S. aureus membrane integrity or hemolysis activity were observed upon treatment (Figure 22-23). 
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4.4 Discussion 
 An increased prevalence of antibiotic resistance threatens to leave humanity with limited 
resources to combat microbial infections. Anti-pathogenic anti-biofilm compounds such as 4EB 
can potentially contribute to controlling this problem. To our knowledge, this work is the first to 
describe the anti-biofilm and antibiotic sensitization effects as well as anti-pathogenic character of 
4EB. This information expands the functionality of 4EB, whose use has previously been associated 
with chemical synthesis or monooxygenase activation (148–150). We think that the BP50/LC50 
method described herein to characterize the activity of 4EB is a novel and effective way to 
recognize anti-pathogenic anti-biofilm compounds. Additionally, this work establishes the 
previously unreported anti-biofilm activities of 3-hydroxybenzoic acid and gentisic acid and 
supports prior findings for protocatechuic acid, salicylic acid, and gallic acid (72, 151–157).  
A structure-activity analysis of compounds related to EEB shed light on the contribution 
of specific molecular components to anti-biofilm activity. By comparing the BP50/LC50 profiles 
of 2-, 3- and 4-hydroxybenzoic acids, it was evident that a hydroxyl group in the ortho position 
significantly reduced both the anti-biofilm and antimicrobial activity. Alkylating the carboxyl 
group of 4-hydroxybenzoic acid to yield methyl paraben slightly reduced the antimicrobial effect 
but substantially increased the anti-biofilm activity. The antimicrobial activity of 4-
hydroxybenzoic acid has been proposed to result from its effect on membrane stability and 
transport processes (72, 151, 158, 159). Although the specific reason remains to be determined, 
methylation enhanced anti-biofilm activity. This finding is significant because methyl paraben is 
widely used in food products and is the subject of controversy related to mammalian toxicity 
resulting from chronic exposure (158, 160). 
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A comparison of di- and trihydroxybenzoic acids indicated that the position of the hydroxyl 
groups impacted anti-biofilm activity. Notably, adding a second hydroxyl group at the 3- position 
to 4-hydroxybenzoic acid (yielding protocatechuic acid) significantly reduced the anti-biofilm 
activity. A third hydroxyl group at the 2- position (gallic acid) substantially reduced both the anti-
microbial and anti-biofilm activity compared to protocatechuic acid. However, methylating the 
carboxyl group of gallic acid to form methyl gallate greatly increased the anti-biofilm activity; 
lengthening of the alkyl moiety (e.g. ethyl gallate and propyl gallate) increased biocidal activity. 
Several mechanisms of antimicrobial activity are known for the alkyl gallates including disruption 
of: membrane stability, polysaccharide production and oxidative phosphorylation (155, 161–163).  
 When elucidating the mechanism of activity of 4EB and structurally related compounds 
against S. aureus biofilm formation, two broad hypotheses must be considered. First, 4EB may 
inhibit biofilm formation through a physicochemical mechanism. In support of this hypothesis, 
4EB reduced the hydrophobicity of S. aureus, which in turn could reduce adhesion and surface 
colonization to negatively charged surfaces such as polystyrene, which was used in the screening 
assay. Charge interactions are known to be a factor in early stage biofilm formation; disruption of 
these interactions negatively impacts biofilm initiation (1, 164). A common feature of the three 
compounds categorized as “anti-pathogenic” in this work (4EB, methyl gallate, methyl paraben) 
was the 4-hydroxybenzoic acid central structure and a single methyl or ethyl moiety on the 
molecule. We hypothesize that the methyl or ethyl group increases the association of the molecules 
with the hydrophobic S. aureus membrane while the negatively charged region of the molecules 
interferes with surface association.  
Second, 4EB may reduce biofilm formation by influencing the transcription of requisite 
genes. Hamamelitannin (HAM), an anti-pathogenic compound with structural similarity to both 
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4EB and methyl gallate, has been reported to prevent S. aureus biofilm formation by altering the 
transcription of quorum sensing and stress response genes via the controversial TRAP 
transcriptional regulator (71, 165). Additionally, the structurally similar molecule gallic acid has 
been reported to act against S. aureus biofilm formation via the ica operon (155). These reports 
suggest that 4EB may also impact biofilm formation on a genetic level. In our work, 4EB was 
found to affect EPS production by S. aureus, increasing both extracellular polysaccharide and 
protein production; this could be the result of alterations in the expression of genes such as ica, 
atl, bap and dltA (151, 166). This physiological change appears to be contradictory to the overall 
anti-biofilm activity of 4EB. However, the increase in EPS production was only evident at high 
4EB concentrations when the corresponding biofilm biomass was low, leading us to hypothesize 
that the increase was a response to stress (20, 167). In general, several plausible mechanisms exist 
by which 4EB can reduce S. aureus biofilm formation. 
 Another feature of 4EB is that it synergized the activity of vancomycin against S. aureus 
biofilm-dwelling cells. In contrast, methyl gallate did not affect vancomycin activity, indicating 
that the interaction between 4EB and vancomycin was not simply due to the presence of a 
secondary compound but rather a characteristic of 4EB. HAM was found to increase vancomycin 
sensitivity by thinning the peptidoglycan cell wall of S. aureus (71). The mechanism by which 
4EB enhanced vancomycin sensitivity is presently unknown, however the effects of HAM on cell 
wall synthesis may act as a lead. 
 This work provides initial data on the anti-pathogenic and anti-biofilm activities of 4EB; 
however, additional effort is required to elucidate the full scope, applications and mechanisms of 
activity of this compound. The experiments reported here were conducted using a single, 
vancomycin-susceptible strain of S. aureus; to better understand the potential of 4EB as an anti-
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biofilm agent, investigations using other S. aureus strains and microbial species are necessary, 
including antibiotic resistant strains. Experiments are also required to determine whether 4EB can 
sensitize pathogens to additional antibiotics beside vancomycin. Phenotypic analyses to elucidate 
the mechanism of 4EB activity revealed impacts on cell hydrophobicity and extracellular 
polysaccharide production. Molecular analyses, including transcriptomics and mutagenesis, will 
help identify and verify the various targets of 4EB.   Overall, the anti-pathogenic and anti-biofilm 
activity of 4EB, along with its ability to potentiate vancomycin sensitivity, warrant its 
consideration as a therapeutic adjuvant to conventional S. aureus biofilm treatments. 
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4.5 Figures and Tables 
 
 
Figure 14. EEB-related compounds tested in this work 
All compounds were structurally similar to the gesho-derived compound ethyl 4-ethoxybenzoic 
acid (EEB). Compounds were selected to investigate the effect of functional group location on 
anti-biofilm activity. 
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Figure 15. Effects of EEB-related compounds on Staphylococcus aureus biofilm formation and 
viability. 
Data points represent the compound concentrations that resulted in half the maximum biofilm 
formation (BP50) and half the maximum planktonic growth (LC50). Compounds were 
characterized as anti-pathogenic, bactericidal or low potency (A). Anti-pathogenic 
concentrations of methyl gallate (B), 4-ethoxybenzoic acid (C) and methyl paraben (D) are 
indicated by arrow heads (B-D). The inoculum cell density is represented by the red dotted line. 
Error bars indicate standard deviation.  
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Table 5. Effect of phenolic acids on Staphylococcus aureus biofilm formation and 
stationary-phase cell viability 
 
 Concentration Biofilm Stationary 
phase cells 
 mg/mL mM % formation1 % inhibition
2 
Log CFU/mL 
Untreated control 0.0 0.0 100 ± 18.3 (68) 0 8.9 ± 1.0 (5) 
Salicylic acid 7.0 
3.5 
1.7 
0.8 
0.4 
50.7 
25.3# 
12.3 
5.8 
2.9 
20.7 ±13.5 (17) 
70.4 ± 28.2 (16) 
137.4 ± 39.0 (16) 
146.6 ± 59.0 (16) 
132.2 ± 30.0 (17) 
79 
30 
0 
0 
0 
6.8 ± 0.2 (3) 
8.2 ± 0.5 (3) 
9.0 ± 0.3 (3) 
9.5 ± 0.0 (1) 
- 
3-hydroxybenzoic 
acid 
3.5 
1.7 
0.8 
0.4 
25.3 
12.3 
5.8 
2.9 
2.9 ± 3.1 (16) 
4.7 ± 7.2 (16) 
111.2 ± 42.3 (16) 
173.1 ± 42.9 (16) 
97 
95 
0 
0 
0.0 ± 0.0 (2)^ 
5.3 ± 1.0 (2)^ 
8.4 ± 0.1 (2) 
- 
p-hydroxybenzoic 
acid 
7.0 
3.5 
1.7 
0.8 
0.4 
0.2 
0.1 
50.7 
25.3 
12.3 
5.8# 
2.9 
1.4 
0.7 
2.0 ± 0.2 (4) 
2.3 ± 0.9 (13) 
1.3 ± 0.9 (17) 
43.4 ± 34.0 (17) 
145.1 ± 37.1 (17) 
119.0 ± 19.6 (17) 
107.5 ± 25.4 (10) 
98 
98 
99 
57 
0 
0 
0 
- 
1.9 ± 3.3 (3)^ 
2.8 ± 2.4 (3)^ 
7.4 ± 1.1 (3) 
8.8 ± 0.2 (3) 
- 
- 
p-hydroxybenzoic 
acid methyl ester 
7.0 
3.5 
1.7 
0.8 
0.4 
0.2 
0.1 
46.0 
23 
11.2# 
5.3# 
2.6# 
1.3# 
0.7 
3.0 ± 4.8 (15) 
1.4 ± 1.2 (18) 
12.0 ± 8.9 (21) 
46.1 ± 15.1 (21) 
66.9 ± 18.1 (22) 
93.3 ± 24.3 (22) 
94.9 ± 3.3 (4) 
97 
99 
88 
54 
33 
7 
5 
- 
4.0 ± 0.7 (2)^ 
7.8 ± 0.7 (5) 
8.8 ± 0.3 (5) 
9.0 ± 0.2 (4) 
9.1 ± 0.4 (2) 
- 
Pyrocatechuic acid 3.5 
1.7 
0.8 
0.4 
22.7 
11.0 
5.2 
2.6 
4.2 ± 2.7 (12) 
3.9 ± 2.0 (12) 
30.5 ± 25.6 (12) 
160.2 ± 19.4 (12) 
96 
96 
70 
0 
0.0 ± 0.0 (2)^ 
0.0 ± 0.0 (2)^ 
6.1 ± 0.7 (2)^ 
8.8 ± 0.0 (2) 
Gentisic acid 3.5 
1.7 
0.8 
0.4 
22.7 
11.0 
5.2 
2.6 
6.8 ± 9.7 (12) 
4.2 ± 7.5 (15) 
151.9 ± 73.1 (15) 
104.7 ± 27.9 (15) 
93 
96 
0 
0 
1.3 ± 1.8 (2)^ 
0.0 ± 0.0 (2)^ 
8.7 ± 0.2 (2) 
9.3 ± 0.3 (2) 
Protocatechuic acid 3.5 
1.7 
0.8 
0.4 
0.2 
22.7 
11.0 
5.2 
2.6 
1.3 
5.3 ± 10.7 (12) 
47.5 ± 32.8 (12) 
124.8 ± 49.4 (15) 
97.1 ± 22.1 (15) 
112.7 ± 14.7 (9) 
95 
53 
0 
3 
0 
0.0 ± 0.0 (2)^ 
6.0 ± 0.9 (2)^ 
8.9 ± 0.2 (2) 
- 
- 
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Table 5 continued.  
 Concentration Biofilm Stationary 
phase cells 
 mg/mL mM % formation1 % inhibition2 Log CFU/mL 
Untreated control 0.0 0.0 100 ± 18.3 (68) 0 8.9 ± 1.0 (5) 
Gallic acid 3.5 
1.7 
0.8 
0.4 
20.6 
10.0# 
4.7 
2.3 
25.5 ± 6.0 (16) 
102.3 ± 78.5 (16) 
168.7 ± 31.4 (16) 
173.3 ± 36.9 (16) 
75 
0 
0 
0 
4.1 ± 0.2 (3)^ 
8.3 ± 0.7 (3) 
8.8 ± 0.1 (3) 
- 
Methyl gallate 3.5 
1.7 
0.8 
0.4 
0.2 
0.1 
19.0 
9.2# 
4.3# 
2.2# 
1.1# 
0.5# 
14.4 ± 7.0 (16) 
23.1 ± 9.6 (16) 
39.9 ± 28.7 (16) 
38.4 ± 23.7 (16) 
42.9 ± 19.0 (12) 
50.6 ± 27.8 (6) 
86 
77 
60 
62 
57 
49 
- 
6.8 ± 0.4 (2) 
7.5 ± 0.3 (4) 
7.5 ± 0.4 (4) 
8.2 ± 0.2 (4) 
8.8 ± 0.2 (4) 
Ethyl gallate 3.5 
1.7 
0.8 
0.4 
0.2 
17.7 
8.6 
4.0 
2.0 
1.0 
15.4 ± 5.6 (16) 
24.9 ± 9.5 (16) 
100.7 ± 81.2 (16) 
75.5 ± 55.2 (16) 
108.3 ± 86.1 (12) 
85 
75 
0 
25 
0 
- 
5.4 ± 0.0 (1)^ 
6.0 ± 0.5 (3)^ 
6.7 ± 0.3 (3) 
7.6 ± 0.2 (3) 
Propyl gallate 3.5 
1.7 
0.8 
0.4 
0.2 
16.5 
8.0 
3.8 
1.9 
0.9 
17.7 ± 6.9 (12) 
22.4 ± 24.7 (12) 
23.2 ± 12.0 (15) 
69.3 ± 58.7 (15) 
146.4 ± 66.0 (12) 
82 
78 
77 
31 
0 
- 
5.6 ± 0.7 (2)^ 
6.2 ± 0.6 (3)^ 
6.9 ± 0.4 (3) 
7.4 ± 0.1 (3) 
4-ethoxybenzoic acid 7.0 
3.5 
1.7 
0.8 
0.4 
0.2 
0.1 
37.3 
21.1 
10.2 
4.8# 
2.4# 
1.2# 
0.6# 
2.5 ± 5.7 (3) 
6.2 ± 12.2 (16) 
11.1 ± 10.6 (16) 
12.1 ± 6.9 (16) 
22.3 ± 11.7 (16) 
62.6 ± 14.0 (12) 
88.5 ± 5.7 (6) 
97 
94 
89 
88 
78 
37 
11 
- 
6.8 ± 0.5 (3) 
6.6 ± 0.4 (3) 
7.8 ± 1.1 (3) 
9.2 ± 0.2 (3) 
9.4 ± 0.2 (3) 
9.5 ± 0.1 (3) 
1Percent biofilm formation are the mean relative to the untreated control ± the standard deviation 
(SD). Parenthetical values are the sample size (n).  
2Percent biofilm inhibition is the difference between the untreated control and the treatment 
^ indicates plate counts below that of the inoculum 6.4 ± 0.1 (n=5). 
# indicates treatment concentrations that inhibited biofilm formation without negatively impacting 
cell growth 
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Table 6. BP50 and LC50 of phenolic acid compounds on Staphylococcus aureus biofilm 
formation and viability 
 
 
Compound 
BP50 LC50 
mM mg/ml mM mg/ml 
methyl gallate 0.82 0.2 18.8 3.5 
ethyl gallate 6.7 1.3 9.8 1.9 
propyl gallate 2.9 0.6 6.6 1.4 
4-ethoxybenzoic acid 1.6 0.3 33.5 5.6 
p-hydroxybenzoic acid 8.0 1.1 14.0 1.9 
methyl paraben 5.7 0.9 22.9 3.5 
3-hydroxybenzoic acid 9.6 1.3 14.0 1.9 
gentisic acid 9.2 1.4 11.0 1.7 
pyrocatechuic acid 4.8 0.7 8.9 1.4 
protocatechuic acid 14.4 2.2 13.2 2.0 
gallic acid 17.3 2.9 21.6 3.7 
salicylic acid 38.5 5.3 46.4 6.4 
EEB+ 1% DMSO 103.6 20.1 818.0 158.9 
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Figure 16. Effect of vancomycin on Staphylococcus aureus planktonic growth. 
Growth of S. aureus after 24 hours of treatment with vancomycin (0.8 μg/ml-1600 μg/ml) was 
assessed to identify the minimal inhibitory concentration (MIC). Details regarding this 
experiment can be found in the materials and method section 4.4 Vancomycin MIC assay. 
Untreated samples (0 μg/ml) served as a negative control. 
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Figure 17. Effects of 4-ethoxybenzoic acid, methyl gallate and methyl paraben on 
Staphylococcus aureus growth. 
Growth of S. aureus in the presence of 0.2 and 0.4 mg/ml 4-ethoxybenzoic acid, 0.2 and 0.4 
mg/ml methyl gallate or 0.8 mg/ml methyl paraben was measured over 24 hours. Untreated (No 
Tx Control) and 1.6 μg/ml vancomycin treated samples served as negative and positive controls, 
respectively. Growth rates were calculated from t= 0 and t= 4 and are presented in table 1 along 
with the percent attenuation. Error bars indicate standard deviation. 
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Table 7. Effects of 4-ethoxybenzoic acid, methyl gallate and methyl paraben on 
Staphylococcus aureus growth rate 
 
Treatment 
Growth rate 
(replications/ hr) 
 
Percent attenuation 
Untreated control 1.11 0 
0.2 mg/ml 4-ethoxybenzoic acid 0.97 12 
0.4 mg/ml 4-ethoxybenzoic acid 0.58 47 
0.2 mg/ml methyl gallate 0.77 30 
0.4 mg/ml methyl gallate 0.59 46 
0.8 mg/ml methyl paraben 0.83 25 
1.6 μg/ml vancomycin 0.0 100 
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Figure 18. Resazurin standard curve. 
The time required for various cell densities to reach maximum fluorescence was plotted and a 
line of best fit was generated. The equation of the curve was used to estimate the quantity of 
viable biofilm-dwelling cells after treatment with 4EB or methyl gallate alone or in combination 
with vancomycin. 
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Table 8. Biocidal effect of vancomycin on biofilm-dwelling cells 
 
 
 
 
 
1Mean cell concentration ± the standard deviation (SD). Parenthetical values are the 
sample size (n). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vancomycin concentration 
(μg/ml) 
Quantity of viable 
biofilm cells (x104)1 
0 2581 ± 463 (3) 
0.8 2440 ± 533 (3) 
1.6 2015 ± 203 (3) 
3.1 773 ± 447 (3) 
6.2 3 ± 3 (2) 
12.5 2 ± 1 (3) 
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Table 9. Biofilm killing activity of compounds in combination with 2.1 mM vancomycin 
 
 
Compound 
 
Concentration 
(mg/ml) 
 
Compound only1 
Percent 
reduction 
compared to 
untreated 
control2 
 
Compound + 
3.1 μg/ml 
vancomycin1 
Percent 
reduction 
compared to 
untreated 
control2 
 
 
4EB 
0 
0.1 
0.2 
0.4 
0.8 
18.6 ± 2.8 (11) 
18.7 ± 1.8 (4) 
17.0 ± 5.3 (4) 
18.3 ± 5.0 (4) 
20.6 ± 3.7 (4) 
- 
0 
9 
2 
0 
2.7 ± 2.2 (11)b 
3.3 ± 1.8 (12)b 
1.5 ± 1.2 (12)b 
0.4 ± 0.5 (9)a,b 
1.0 ± 1.1 (12)a,b 
- 
0 
44 
85 
63 
 
 
Methyl 
gallate 
0 
0.1 
0.2 
0.4 
0.8 
18.6 ± 2.8 (11) 
15.7 ± 6.7 (4) 
15.8 ± 8.5 (4) 
16.2 ± 12.3 (4) 
28.1 ± 9.9 (4) 
- 
16 
15 
13 
0 
2.7 ± 2.2 (11)b 
3.2 ± 1.9 (11)b 
3.3 ± 2.2 (12)b 
5.7 ± 4.2 (12)b 
5.4 ± 7.6 (12)b 
- 
0 
0 
0 
0 
 
1Mean colony forming units per milliliter (x106) ± the standard deviation (SD). Parenthetical 
values are the sample size (n). 
2Percent reduction are the mean of treated samples relative to the untreated or vancomycin only 
treated controls. Controls contain 0 mg/ml of compound. 
(a) Indicated a significant difference (p<0.05) between vancomycin and combination treated 
samples.  
(b) Indicated a significant difference between the compound and combination treated samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
* 
84 
 
Figure 19. Effects of 4-ethoxybenzoic acid on Staphylococcus aureus hydrophobicity. 
The hydrophobicity of cells treated with 4-ethoxybenzoic acid were categorized as low (≤50), 
moderate (50%-70%) or high (≥70%). Untreated samples served as a negative control. Error bars 
indicate standard deviation. ANOVA Tukey’s tests were performed; asterisks (*) indicated a 
significant difference (p< 0.05) between the treated samples and untreated control. 
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Figure 20. Crystal violet standard curve. 
Colony counts that correlated to crystal violet measurements were plotted and a line of best fit 
was generated. The equation of the curve was used to estimate the quantity of biofilm-dwelling 
cells in EPS production assays. 
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Figure 21. Effect of 4EB on Staphylococcus aureus extracellular polysaccharide, protein and 
DNA production. 
Biofilm-associated polysaccharide (A), protein (B) and extracellular DNA (C) production was 
quantified using fluorescent dyes (grey bars). The corresponding biofilm cell counts are 
presented on the secondary y-axis (black line). Untreated samples served as negative controls. 
Error bars indicate standard deviation. ANOVA tests were performed; asterisks (*) indicated a 
significant difference (p< 0.05) in polysaccharide production between the treated samples and 
untreated control. 
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Figure 22. Effects of 4-ethoxybenzoic acid on Staphylococcus aureus membrane integrity. 
Bars represent propidium iodide fluorescence intensity which is an indicator of membrane 
permeability. The untreated and heat treated samples acted as negative and positive control, 
respectively. Error bars indicate standard deviation. 
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Figure 23. Effects of 4-ethoxybenzoic acid on Staphylococcus aureus hemolytic activity. 
Bars represent the presence of hemolytic activity on rabbit red blood cells. The untreated, 10% 
SDS treated and 0.1% TritonX-100 treated samples acted as negative controls and 1.6 µg/ml 
vancomycin was used as a the positive control. 
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5 CONCLUSIONS 
Plants have been found to be a source of a variety of antimicrobial and anti-biofilm compounds 
(69, 70, 168, 169); Rhamnus prinoides is among these ethnopharmacologically relevant plant 
species. In this project, we identified and characterized the antimicrobial and anti-biofilm activities 
of gesho extracts and derived compounds on a variety of microorganisms including the 
opportunistic pathogens Staphylococcus aureus, Streptococcus mutans, Pseudomonas aeruginosa, 
and Candaida albicans. Gesho ethanol extracts were found to significantly inhibit mono-species 
biofilm formation via bactericidal, bacteriostatic and anti-pathogenic mechanisms in a species 
dependent manner. Additionally, GSE was found to inhibit S. mutans and C. albicans dual-species 
biofilm formation and to disrupt their synergistic relationship. Among these findings, the anti-
pathogenic anti-biofilm activities of GLE on S. aureus and GSE on C. albicans were of great 
interest due to their possible applications as anti-pathogenic therapeutics. Further investigations 
into the chemical composition of GLE identified two compound of interest, ethyl 4-ethoxybenzoic 
acid (EEB) and 4-hydroxy-4-methyl pentanone (HMP); both compounds exhibited anti-
pathogenic, anti-biofilm activity against S. aureus biofilms. Interestingly, HMP also significantly 
reduced biofilm formation of P. aeruginosa. Further investigations into this observation were not 
conducted, however the fact that HMP was able to inhibit biofilm formation of a resilient Gram 
negative bacterial species combined with the lack of antimicrobial studies on this compound 
warrants further investigations into its use as an anti-biofilm agent. 
The anti-pathogenic, anti-biofilm activity of EEB on S. aureus led to a structure-activity 
analysis of structurally similar phenolic compounds. This analysis identified 4-ethoxybenzoic acid 
(4EB), methyl gallate and methyl paraben as three compounds that inhibited S. aureus biofilm 
formation in an anti-pathogenic manner; 4EB also exhibited synergism with vancomycin 
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significantly decreasing the number of biofilm-dwelling cells when compared to treatments with 
vancomycin alone. Investigations into the phenotypic effects of 4EB on S. aureus found that 4EB 
negatively impacted cell hydrophobicity and enhanced relative extracellular polysaccharide 
production. Taken together, this data suggested that 4EB may have future applications in topical 
antiseptic or surface disinfectant. Transcriptomic and mutagenesis experiments along with in vitro 
and in vivo toxicology studies will go a long way to achieving this goal. Additionally, the impacts 
of 4EB on S. aureus have led to current investigations into the effects of 4EB on biofilm formation 
by other bacterial and fungal species; preliminary data from these experiments have been quite 
promising and point to even more directions that this project can take.     
The proliferation of antimicrobial resistance is a serious threat to human health and highlights 
the need for research on novel therapeutics such as anti-pathogenic compounds. Traditional 
medicine and phototherapeutics have been and continue to be a great source of antimicrobial agents 
as plants have evolved to produce a variety of compounds that prevent microbial colonization and 
discourage herbivory (170). Our work with Rhamnus prinoides extracts and derived compounds 
expands our repertoire of plant-based therapeutics and provides novel insights into applications of 
gesho. There are many directions that this project can be take going forward for both gesho extracts 
and gesho-derived compounds. Someday the fruits of the project may positively impact the lives 
of people around the world.  
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Appendix A 
 
Table 10. PCR primers for S. mutans and C. albicans strain identification 
Species Primer name Primer sequence Source 
S
. 
m
u
ta
n
s 
8UA fwd 5’-AGAGTTTGATCCTGGCTCAG-3’ (Fujiwara et al., 2001) 
1540R rvs 5’-AAGGAGGTGATCCAGCC-3’ (Fujiwara et al., 2001) 
16S mid seq fwd 5’-AGATACCCTGGTAGTCCACG-3’ (Campbell et al. 2020) 
16S mid seq rvs 5’-CGTGGACTACCAGGGTATCT-3’ (Campbell et al. 2020) 
TF9911 fwd 5’-GAAGTCGTAACAAGGTAGCCGT-3’ (Fujiwara et al., 2001) 
TF9912 rvs 5’-TGCCAAGGCATCCACC-3’ (Fujiwara et al., 2001) 
C
. 
a
lb
ic
a
n
s 18S rRNA fwd 5’-TATCTGGTTGATCCTGCCAG-3’ (Campbell et al. 2020) 
18S rRNA rvs 5’-TCGATAGTCCCTCTAAGAAGTG-3' (Teymuri et al., 2015) 
ITS1 rvs 5’-CCGCAGGTTCACCTACGGA-3’ (McCullough, Clemons 
& Stevens, 1999) ITS4 rvs 5’-TCCTCCGCTTATTGATATGC-3’ 
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>S. mutans_16S rRNA and 16S-23S intergenic spacer contig sequence (Genbank accession#: 
MT318140) 
TTGCCAAGGGCACCACCGTGCGCCCTTATTAACTTAACCTTATTTCTCGTTTCTCTGGCTTTTC
AGCGTCTCGGTTTCTTTCTTGTTCCCCTATAGCTGCGCTATAGGGCTTTTACTAGCTATTCAAT
TGTCAATGAACCATCTCTAGGATACTTATCATATCCTAAGTGGATTTTATAGACTTCCTTGTC
TTAAACAAGATATGAAGTTGAACTCCAGACTGACTTCTTAGAAAAATAGATCATCTTCTACA
GAAGTATTCGCAAGCGAACCGTCTGTTAGTATCCTGTTTTAATGGAGCCTAGCGGGATCGAA
CCGCTGACCTCCTGCGTGCAAAGCAGGCGCTCTCCCAGCTGAGCTAAGGCCCCACTTACCCT
CTCAAAACTAAACAAGAAGTTCCCCTAACGTGCTTTGCGTTTTTCCTTAGAAAGGAGGTGAT
CCAGCCGCACCTTCCGATACGGCTACCTTGTTACGACTTCACCCCAATCATCCATCCCACCTT
AGGCGGCTGGCCCCTAAAAGGTTACCTCACCGACTTCGGGTGTTACAAACTCTCGTGGTGTG
ACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCGTGCTGATCCGCGATTACTA
GCGATTCCGACTTCATGGAGGCGAGTTGCAGCCTCCAATCCGAACTGAGATCGGCTTTCAGA
GATTAGCTTGCCGTCACCGGCTCGCAACTCGTTGTACCGACCATTGTAGCACGTGTGTAGCC
CAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCGGTTTATTACCGGCA
GTCTCGCTAGAGTGCCCAACTTAATGATGGCAACTAACAATAAGGGTTGCGCTCGTTGCGGG
ACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTCTCCGATGTA
CCGAAGTAACTTCCTATCTCTAAGAATAGCATCGGGATGTCAAGACCTGGTAAGGTTCTTCG
CGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGT
TTCAACCTTGCGGTCGTACTCCCCAGGCGGAGTGCTTATTGCGTTAGCTCCGGCACTAAGCC
CCGGAAAGGGCCTAACACCTAGCACTCATCGTTTACGGCGTGGACTACCAGGGTATCTAATC
CTGTTCGCTACCCACGCTTTCGAGCCTCAGCGTCAGTGACAGACCAGAGAGCCGCTTTCGCC
ACTGGTGTTCCTCCATATATCTACGCATTTCACCGCTACACATGGAATTCCACTCTCCCCTTC
TGCACTCAAGTCAGACAGTTTCCAGAGCACACTATGGTTGAGCCATAGCCTTTTACTCCAGA
CTTTCCTGACCGCCTGCGCTCCCTTTACGCCCAATAAATCCGGACAACGCTCGGGACCTACG
TATTACCGCGGCTGCTGGCACGTAGTTAGCCGTCCCTTTCTGGTAAGCTACCGTCACTGTGTG
AACTTTCCACTCTCACACACGTTCTTGACTTACAACAGAGCTTTACGATCCGAAAACCTTCTT
CACTCACGCGGCGTTGCTCGGTCAGACTTTCGTCCATTGCCGAAGATTCCCTACTGCTGCCTC
CCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGATCACCCTCTCAGGTCGGCTAT
GTATCGTCGCCTTGGTAAGCTCTTACCTTACCAACTAGCTAATACAACGCAGGTCCATCTACT
AGTGATGCGCTTGCATCTTTCAATCAATTATCATGCAATAATTAATATTATGCGGTATTAGCT
ATCGTTTCCAATAGTTATCCCCCGCTAATAGGCAGGTTACCTACGCGTTACTCACCCGTTCGC
GACTCAAGAAAACACGGTGTGCAAGCACAGTGTGTTCTCTTGCGTCCCACTTGCATGTATTA
GGCACGCCGCCAGCGTTCGTCCTGAGC 
 
Figure 24.Streptococcus mutans 16S rRNA and 16S-23S intergenic spacer gene sequence. 
Segments of the S. mutans 16S rRNA and the 16S-23S intergenic region were amplified and 
sequenced using the 8UA fwd, MUT-R rvs, 16S mid seq fwd, 16S mid seq rvs, TF9911F and 
TF9912R primers. Sequences were then aligned using the analysis software DNA Base 
Assembler v5.15.0 to assemble a single contig. 
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>C. albicans_18S rRNA-ITS4 contig sequence (Genbank accession#: MT166273) 
TTGAGGTCAAGTTTGAAGATATACGTGGTGGACGTTACCGCCGCAAGCAATGTTTTTGGTTA
GACCTAAGCCATTGTCAAAGCGATCCCGCCTTACCACTACCGTCTTTCAAGCAAACCCAAGT
CGTATTGCTCAACACCAAACCCAGCGGTTTGAGGGAGAAACGACGCTCAAACAGGCATGCC
CTCCGGAATACCAGAGGGCGCAATGTGCGTTCAAAGATTCGATGATTCACGAATATCTGCAA
TTCATATTACGTATCGCATTTCGCTGCGTTCTTCATCGATGCGAGAACCAAGAGATCCGTTGT
TGAAAGTTTTGACTATTAGTAATAATCTGGTGTGACAAGTTGATAAAAAATTGGTTGTAAGT
TTAGACCTCTGGCGGCAGGCTGGGCCCACCGCCAAAGCAAGTTTGTTTCAAAGAAAAACAC
ATGTGGTGCAATTAAGCAAATCAGTAATGATCCTTCCGCAGGTTCACCTACGGAAACCTTGT
TACGACTTTTACTTCCTCTAAATGACCAAGTTTGACCAGCTTCTCGGTTCCAGAATGGAGTTG
CCCCCTTTCCTAAACCAATCCGGAGGCCTCACTAAGCCATTCAATCGGTAGTAGCGACGGGC
GGTGTGTACAAAGGGCAGGGACGTAATCAACGCAAGCTGATGACTTGCGCTTACTAGGAAT
TCCTCGTTGAAGAGCAACAATTACAATGCTCTATCCCCAGCACGACGGAGTTTCACAAGATT
TCCCAGACCTCTCGGCCAAGGCTTATACTCGCTGGCTCCGTCAGTGTAGCGCGCGTGCGGCC
CAGAACGTCTAAGGGCATCACAGACCTGTTATTGCCTCAAACTTCCATCGACTTGAAATCGA
TAGTCCCTCTAAGAAGTGACTATACCAGCAAATGCTAGCAGCACTATTTAGTAGGTTAAGGT
CTCGTTCGTTATCGCAATTAAGCAGACAAATCACTCCACCAACTAAGAACGGCCATGCACCA
CCACCCACAAAATCAAGAAAGAGCTCTCAATCTGTCAATCCTTATTGTGTCTGGACCTGGTG
AGTTTCCCCGTGTTGAGTCAAATTAAGCCGCAGGCTCCACTCCTGGTGGTGCCCTTCCGTCAA
TTCCTTTAAGTTTCAGCCTTGCGACCATACTCCCCCCAGAACCCAAAGACTTTGATTTCTCGT
AAGGTGCCGATTGCGTCAATAAAAGAACAACAACCGATCCCTAGTCGGCATAGTTTATGGTT
AAGACTACGACGGTATCTGATCATCTTCGATCCCCTAACTTTCGTTCTTGATTAATGAAAACG
TCCTTGGTAAATGCTTTCGCAGTAGTTAGTCTTCAGTAAATCCAAGAATTTCACCTCTGACAA
CTGAATACTGATACCCCCGACCGTCCCTATTAATCATTACGATGGTCCTAGAAACCAACAAA
ATAGAACCATAACGTCCTATTCTATTATTCCATGCTAATATATTCGAGCAAAGGCCTGCTTTG
AACACTCTAATTTTTTCAAAGTAAAAGTCCTGGTTCGCCCATAAATGGCTACCCAGAAGGAA
AGGCTCGGCTGGGTCCAGTACGCATCAAAAAAGATGGACCGGCCAGCCAAGCCCAAGGTTC
AACTACGAGCTTTTTAACTGCAACAACTTTAATATACGCTTTTGGAGCTGGAATTACCGCGG
CTGCTGGCACCAGACTTGCCCTCCAATTGTTCCTCGTTAAGGTATTTACATTGTACTCATTCC
AATTACAAGACCCAAAAGGGCCCTGTATCGTTATTTATTGTCACTACCTCCCCGTGTCGGGA
TTGGGTAATTTGCGCGCCTGCTGCCTTCCTTGGATGTGGTAGCCGTTTCTCAGGCTCCCTCTC
CGGAATCGAACCCTTATTCCCCGTTACCCGTTGAAACCATGGTAGGCCACTATCCTACCATC
GAAAGTTGATAGGGCAGAAATTTGAATGAACCATCGCCAGCACAAGGCCATGCGATTCGAA
AAGTTATTATGAATCATCAAAGAGCCCGAAGGCATTGATTTTTTATCTAATAAATACATCCC
TTCCAAACAGTCGGGATTTTAAGCATGTATTAGCTCTAGAATTACCACGGTTATCCAAGTAG
TAAGGTACTATCAAATAAACGATAACTGATTTAATGAGCCATTCGCAGTTTCACTGTATAAA
TTGCTTATACTTAGACATGCATGG 
 
Figure 25. Candida albicans 18S rRNA and ITS gene sequencing contig. 
Segments of the C. albicans 18S rRNA and ITS1-4 genes were amplified and sequenced using 
the 18S fwd, 18S rvs, ITS1 rvs and ITS4 rvs primers. Sequences were then aligned using the 
analysis software DNA Base Assembler v5.15.0 to assemble a single contig.  
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Table 11. BLAST results for strain identification 
 Description Query 
Cover 
E-value Percent 
identity 
Accession 
S
. 
m
u
ta
n
s 
Streptococcus mutans strain T8 99% 0.0 99.85% CP044492.1 
Streptococcus mutans strain LAR01 99% 0.0 99.69% CP023477.1 
Streptococcus mutans strain UA96 99% 0.0 99.69% AF139600.1 
Streptococcus mutans strain UA140 99% 0.0 99.64% CP044495.1 
Streptococcus mutans strain NN2025 99% 0.0 99.64% AP010655.1 
C
. 
a
lb
ic
a
n
s Candida albicans strain ATCC 18804 76% 0.0 99.82% HQ876034.1 
Candida albicans strain SC5314-P0 100% 0.0 99.77% CP025165.1 
Candida albicans strain SC5314-GTH12 100% 0.0 99.77% CP025182.1 
Candida albicans strain SC5314 79% 0.0 99.75% XR_002086442.1 
Candida albicans strain TIMM 1768 100% 0.0 99.77% CP032012.1 
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Appendix B 
Table 12. Metabolic activity of Streptococcus mutans and Candida albicans biofilm 
dwelling cells after exposure to ethanol and aqueous gesho extracts 
 
 
 
 
 
 
 
 
 
  Streptococcus mutans Candida albicans S. mutans and C. albicans 
Extract Concentration 
(mg/mL) 
% metabolic 
activity2 
% biofilm 
inhibition 
% metabolic 
activity2 
% biofilm 
inhibition 
% metabolic 
activity2 
% biofilm 
inhibition 
Control 0 100 ± 1.9 0 100 ± 0.9 0 100 ± 0.6 0 
GLE1 0.2 
0.5 
1 
3 
5 
7 
87 ± 4 
80 ± 6 
76 ± 9 
63 ± 11* 
59 ± 11* 
55 ± 10 * 
13 
20 
24 
37 
41 
45 
91 ± 2* 
88 ± 2* 
93 ± 1* 
104 ± 1 
102 ± 1 
103 ± 1 
9 
12 
7 
0 
0 
0 
103 ± 3 
102 ± 3 
103 ± 4 
107 ± 2 
113 ± 2* 
111 ± 5* 
0 
0 
0 
0 
0 
0 
GLW1 0.2 
0.5 
1 
3 
5 
7 
94 ± 2 
91 ± 2* 
90 ± 3* 
93 ± 2 
95 ± 2 
95 ± 3 
6 
9 
10 
7 
5 
5 
55 ± 3* 
46 ± 3* 
39 ± 2* 
23 ± 2* 
30 ± 2* 
29 ± 2* 
45 
54 
61 
67 
70 
71 
98 ± 2 
94 ± 3 
93 ± 3 
87 ± 2* 
84 ± 2* 
85 ± 2* 
2 
6 
7 
13 
16 
15 
GSE1 0.2 
0.5 
1 
3 
5 
7 
66 ± 6* 
51 ± 7* 
37 ± 9* 
23 ± 5* 
31 ± 3* 
23 ± 4* 
34 
49 
63 
77 
69 
77 
73 ± 3* 
67 ± 2* 
60 ± 3* 
56 ± 2* 
53 ± 2* 
54 ± 1* 
27 
33 
40 
44 
47 
46 
108 ± 4 
121 ± 7* 
131 ± 4* 
145 ± 5* 
152 ± 2* 
164 ± 6* 
0 
0 
0 
0 
0 
0 
GSW1 0.2 
0.5 
1 
3 
5 
7 
95 ± 2 
94 ± 2 
96 ± 2 
93 ± 2 
93 ± 2 
95 ± 3 
5 
6 
4 
7 
7 
5 
87 ± 2* 
78 ± 2* 
73 ± 2* 
62 ± 1* 
57 ± 1* 
49 ± 2* 
13 
22 
27 
38 
43 
51 
90 ± 3 
99 ± 4 
99 ± 3 
104 ± 3 
105 ± 2 
109 ± 3 
10 
1 
1 
0 
0 
0 
1Leaf ethanol (GLE), leaf water (GLW), stem ethanol (GSE) and stem water (GSW) treatments  
2Percent biofilm formation are the mean of extract treated samples relative to the untreated 
control for each species± the standard error of the mean (SEM).  
*indicate a significant difference (p< 0.05) between the treated samples 
 
 
